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ABBREVIATIONS    Ab    antibody Ag    antigen AID    activation‐induced desaminase Aly    alymphoplasia APC    antigen presenting cell BAFF    B cell‐activating factor BALT    bronchial‐associated lymphoid tissue BBB    blood brain barrier BM    bone marrow BMC    bone marrow chimera BrdU    bromdesoxyuridin CCL    chemokine ligand CCR    chemokine receptor CDR    complementary determining region CFA    complete Freund adjuvant CFSE    carboxyfluorescein succinimidyl ester cIAP    cellular inhibitor of apoptosis CMI    cell‐mediated immunity CNS    central nervous system CTL    cytotoxic T lymphocyte DC    dendritic cell DTH    delayed type hypersensitivity DTR    diphteria toxin receptor DTx    diphteria toxin EAE    experimental autoimmune encephalomyelitis EBV    Eppstein‐Barr virus FCS    fetal calf serum FDCs    follicular dendritic cell GALT    gut‐associated lymphoid tissue GC    germinal center GM‐CSF  granulocyte/macrophage‐colony stimulating factor HEV    high endothelial venule HLA    human leukocyte antigen ICAM    inter‐cellular adhesion molecule Ig    immunoglobulin IKK    inhibitor kappa B kinase Il    interleukin IFN    interferon KLH    keyhole limpet hemocyanin LN    lymph node         LPS    lipopolysaccharid LT    lymphotoxin  MALT    mucosal‐associated lymphoid tissue 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MHC    major histocompatibility complex MOG    myelin oligodendrocyte protein MBP    myelin basic protein MS    multiple sclerosis mTEC    medullary thymic epithelial cells NALT    nasal‐associated lymphoid tissue NFκB    nuclear factor kappa B  NIK    nuclear factor kappa B ‐inducing kinase OVA    ovalbumin PALS    periarteriolar lymphoid sheath PAMPs  pathogen‐associated molecular patterns  pDC    plasmacytoid dendritic cell PELS    periellipsoid lymphoid sheath PLT    primary lymphoid tissue plt    paucity of LN T cells PLP    proteolipid protein PP    Peyers patch PRR    pattern‐recognition receptor PTA    peripheral tissue antigens PTx    pertussis toxin Rag    recombination activating gene RANK    receptor activator of NFκB SEM    standard error of mean SLT    secondary lymphoid tissue TCR    T cell receptor TGF‐β    transforming growth factor beta Th    helper T cell TLR    toll‐like receptor TLT    tertiary lymphoid tissue TNF    tumor necrosis factor TNFR    tumor necrosis factor receptor TRAF    TNF receptor‐associated factor Treg    regulatory T cell TMEV    Theiler`s murine encephalomyelitis virus TWEAK  TNF‐like weak inducer of apoptosis VCAM    vascular cell adhesion protein VLR    variable lymphocyte receptors   Wt    wildtype 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ZUSAMMENFASSUNG   Die  Vorstellung,  dass  sekundäre  lymphatische  Organe  (SLOs)  eine  kritische Vorraussetzung  für  die  Aktivierung  von  Lymphozyten  sind,  wird  von  der Beobachtung  gestützt,  dass  alymphoplastische  (NIKaly/aly)  Mäuse,  die  keine Lymphknoten  oder  Peyer  Plaques  besitzen,  beeinträchtigte  Immunität gegenüber  Tumoren  und  Vakzinen  aufweisen.  Die  strukturellen  Fehlbildungen von  NIKaly/aly  Mäusen  werden  durch  eine  Mutation  der  NFkB‐induzierenden Kinase  (NIK)  bedingt,  welche  den  nicht‐kanonischen  NFkB‐Signalweg  aktiviert und  Signale  vom  Lymphotoxin‐β‐Rezeptor  transduziert.  Letzterer  ist  an  der Entwicklungsanlage von SLOs entscheidend beteiligt. Die Möglichkeit, dass NIK eine  Rolle  als  Signalinstanz  in  der  Immunaktivierung  des  ausgereiften Organismus  spielt,  wurde  bisher  vernachlässigt.  Überraschenderweise  haben wir  entdeckt,  dass  die  Immundefizienz  von  NIKaly/aly  Mäusen  teilweise  in  der Rolle von NIK in der T‐Zellaktivierung begründet  liegt und unabhängig von der Abwesenheit  von  SLOs  ist. Während  B‐Zellaktivierung  vom  lymphoretikulären System  und  germinalen  Zentren  abhängt,  um  Antikörper‐sekretierende Plasmazellen  zu  erzeugen,  fungiert  T‐Zellimmunität  komplett  unabhängig  von spezifischen SLO‐Strukturen. Hiermit beschreiben wir ein alternatives Modell für die  Induktion  von  zellvermittelter  Immunität,  bei  der  antigenpräsentierende Zellen  Antigene  aufnehmen  und  in  die  Leber migrieren,  wo  sie  neolymphoide Aggregate  bilden.  Diese  Strukturen  reichen  nicht  aus  um  Affinitätsreifung  und Klassenwechsel von B‐Zellen zu ermöglichen, aber sie bieten eine Umgebung, die als Ersatz zur Erzeugung zellvermittelter Immunität dienen kann.  Auch wenn wir  beschreiben,  dass  die  Immundefizienz  von NIKaly/aly Mäusen  in unausreichender T‐Zellaktivierung begründet liegt, zeigen wir nun, dass die NIK‐Mutation  in  NIKaly/aly  Mäusen  nicht  zu  einem  T‐Zellintrinsischem  Defekt  führt, sondern zu einer Fehlfunktion in dendritischen Zellen, CD4+ Effektorzelllinien zu kreieren.  Die  Expression  von  NIK  spezifisch  in  dendritischen  Zellen  ist ausreichend,  um  zellvermittelte  Immunität  wiederherzustellen.  Wir  konnten jedoch  zeigen,  dass  die  pure  Anwesenheit  von  NIK‐suffizienten 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antigenpräsentierenden  Zellen  nicht  genügt,  um  reife  NIK‐defiziente  CD4+  T‐Zellen  zu  aktivieren.  Vielmehr  müssen  NIK‐defiziente  CD4+  T‐Zellen  eine  T‐Zellentwicklung  im  Thymus  in  Anwesenheit  NIK‐suffizienter  dendritischer Zellen durchlaufen, um ein funktionales Effektorrepertoir zu bilden. Damit haben wir  entdeckt,  dass  eine  Population  von  thymischen  dendritischen  Zellen  NIK benötigt,  um  T‐Zelleffektorlinien  während  der  thymischen  Entwicklung  zu bilden. 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SUMMARY   The notion that secondary lymphoid tissues (SLTs) are an absolute requirement for  lymphocyte  activation  is  supported  by  the  finding  that  alymphoplastic (NIKaly/aly) mice lacking lymph nodes (LNs) and peyer's patches display impaired immunity  to  tumors  as well  as  vaccines.  The  developmental malformations  of such  NIKaly/aly  mice  are  due  to  a  mutation  in  the  NFkB‐inducing  kinase  (NIK), which activates the non‐canonical NFkB pathway and is crucial for lymphotoxin‐β receptor signaling. The latter is vitally involved in the formation of SLTs during development. Hence, the role of NIK as a signaling entity in immune activation in the mature organism has been somewhat overlooked. To our surprise, we found that the immunodeficiency of NIKaly/aly mice results from the impact of NIK on T cell priming but not from the lack of SLTs. We clearly demonstrate that while B cell  activation  requires  a  lymphoreticular  system  and  germinal  center  (GC) formation  for  the  generation  of  antibody‐secreting  plasma  cells,  against  all conventional  wisdom,  T  cell  immunity  appears  to  function  completely independent  of  the  structures  provided  by  SLTs.  We  describe  an  alternative pathway  for  the  induction  of  cell‐mediated  immunity  (CMI),  in which  antigen‐presenting  cells  (APCs)  sample  antigen  and migrate  into  the  liver  where  they induce  neo‐lymphoid  aggregates.  These  structures  are  insufficient  to  support affinity  maturation  and  class  switching,  but  provide  a  novel  surrogate environment for the initiation of CMI. Although the immuno‐deficiency in NIKaly/aly mice results from insufficient T cell priming, we  further demonstrate  that  the NIK‐lesion  in NIKaly/aly mice does not cause  an  intrinsic  CD4+  T  cell  defect  but  leads  to  the  failure  of  dendritic  cells (DCs)  to  licence  CD4+  effector  lineages.  We  discovered  that  DC‐restricted expression  of  NIK  is  sufficient  to  restore  effective  CMI.  However,  adoptive transfer experiments have shown that the pure presence of NIK‐sufficient APCs is  not  suitable  to prime NIK‐lesioned  adult  CD4+ T  cells  to  develop pathogenic effector  properties.  Yet,  NIK‐lesioned  CD4+  T  cells  need  to  undergo  thymic development in the presence of NIK‐sufficient DCs in order to shape the effector 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repertoire. By systematically studying the function of NIK in CMI, we discovered that  a  population  of  thymic  DCs  requires  NIK  and  is  capable  to  shape  the formation of T effector lineages during development. 




THE IMMUNE SYSTEM  Pathogens  such  as  viruses,  bacteria,  fungi  and  helminthes,  constantly  threaten the human body and ensure their survival by exploiting the host’s resources. The immune system protects the body against diseases by attacking and eliminating invaders. Although the immune system is found in all creatures including plants, it has evolved to its highest complexity in mammals. It consists of different types of specific proteins, cells and organs that interact in a dynamic network.  In  general  terms,  it  can  be  divided  into  two  categories:  the  innate  and  the adaptive  immune  system  [1].  However,  innate  and  adaptive  immunity  are bridged and depend on each other on several levels. The innate immune system is  evolutionary  ancient  and  recognizes  components  that  are  conserved  among broad groups of pathogens. Due to its rapid activation it represents the first line of  defense  against  invaders.  Phagocytic  cells  such  as macrophages, monocytes, dendritic cells and neutrophiles recognize patterns of the invader such as viral or bacterial DNA and cell wall components by specified receptors. Phagocytosis not only  leads  to  the  destruction  of  the  pathogen,  but  also  causes  the  release  of inflammatory mediators that ultimately recruit other immune cells to the site of infection. However, the innate immune system is non‐specific and does not lead to long‐lasting immunity. In contrast, the adaptive immune system is pathogen‐specific and has evolved only in vertebrates. It acts much slower than the innate immune system and is dependent on innate immune cells for activation. The cells of the adaptive immune system are known as thymus‐ and bone marrow‐derived lymphocytes  (T‐  and  B  cells,  respectively).  They  carry  receptors,  which  are generated by somatic recombination and recognize components that are specific to  the  pathogen,  so‐called  antigens.  B  cells  that  recognize  the  antigen  via  a membrane‐bound  immunoglobulin  (B  cell  receptor)  will  produce  and  secrete antigen‐specific antibodies. Antibodies can either directly neutralize the antigen, such  as  bacterial  toxins,  or  induce  secondary  immune  functions  such  as  the 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activation of  the complement system, an association of small proteins that  lead to  the  lysis  of  infected  cells  via  a  membrane  attack  complex.  T  cells  can  be divided  into different subsets  that are phenotypically distinct  in  the expression of  clusters  of  differentiation  (CD),  but  more  importantly  play  functionally discrete roles.  CD8+ and CD4+ T cells are characterized by the expression of a T cell  receptor  (TCR)  that  consists  of  one α  and one β  chain. While  CD8+ T  cells have  cytotoxic  activity  and  can  destroy  infected  cells  and  tissues,  CD4+  T  cells provide  help  to  B  cells  and  secrete  cytokines  that  attract  and  activate  other immune cells. Another minor T cell subset carries a TCR consisting of one γ and one δ  chain  (γδ  T  cells).  These T  cells  are often  classified  as part  of  the  innate immune  system  due  to  that  the  specificity  of  their  TCR  often  is  restricted  to common molecules produced by microbes.  γδ T cells are predominantly found in the gut but also occur in other organs such as in the skin.  The  evolutionary  advantage  of  the  adaptive  immune  system  compared  to  the innate  immune  system  is  that  it  has  the  capacity  to  “remember”.  The immunological  memory  is  based  on  the  preexistence  of  a  clonally  expanded population of antigen‐specific lymphocytes that allows a more rapid and efficient action  when  the  organism  repetitively  encounters  the  same  pathogen.  In  the course  of  evolution,  the  appearance  of  adaptive  immunity  coincided  with  the development and complexification of  lymphoid organs. These organs provide a microenvironment in which cells of the innate and adaptive immune system can meet and interact efficiently. Lymphoid structures are believed to be crucial for the  induction of both B cell‐driven (humoral) and T cell‐driven (cell‐mediated) immunity.  This  thesis  will  mainly  focus  on  the  structural  and  molecular requirements  of  cell‐mediated  immunity  (CMI)  using  a  model  of  T  cell‐driven autoimmunity. The following chapters will introduce the structure and function of  lymphoid  organs  in more  detail.  Subsequently,  different  aspects  (functional and  molecular)  of  T  cell  development,  activation  as  well  as  tolerance  and autoimmunity  will  be  discussed.  Introducing  important  signaling  pathways  as well as the mouse disease model used in this work will follow in order to provide the  reader with  fundamental  knowledge  to  understand  the work  presented  in this thesis. 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LYMPHOID TISSUES: WHERE T CELLS DEVELOP AND POLARIZE     Three types of lymphoid tissues can be distinguished.   While primary lymphoid tissues are a place of hematopoiesis and development of lymphocytes, secondary and tertiary  lymphoid tissues are places where  immune cells become activated to  convert  into effector  cells. The  following  chapter will  explain both  structure and  their  function,  specifically  in  cell‐mediated  immunity,  of  these  lymphoid tissues.   PRIMARY LYMPHOID TISSUES   Bone marrow and thymus are the classical primary lymphoid tissues (PLTs). The bone marrow is the site where hematopoietic multipotent stem cells give rise to all blood cell types including myeloid and lymphoid lineages. Myeloid precursors develop into macrophages, neutrophiles, basophiles, eosinophiles, erythrocytes, megakaryocytes  and  dendritic  cells  (DCs).  Lymphoid  precursors  give  rise  to T cells and B cells as well as natural killer  (NK) cells. While B cell development occurs within  the  bone marrow, T cell  development  occurs within  the  thymus. Therefore,  T cell  progenitors  migrate  from  the  bone  marrow  to  the  thymus where they undergo clonal expansion and several selection processes, until they can leave the thymus as mature T cells.  THYMIC T CELL DEVELOPMENT    The  thymus  is  a  tissue  without  any  self‐renewing  potential  and  is  therefore depending on the immigration of new progenitors from blood and bone marrow [2].  It is a two‐lobed organ situated just below the upper end of the sternum and can  be  morphologically  divided  into  the  outer  cortex  and  the  inner  medulla, through which within  approximately  20  days  thymocytes migrate  in  a  strictly organized fashion during their development (Figure 1). The earliest precursors 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that enter the thymus derive from hematopoietic stem cells in the bone marrow and  are  known  as  early  T  cell  progenitors.  These  cells  home  to  the  thymus through  the  cortico‐medullary  junction  and  are  not  yet  T  lineage  committed.  They do not yet express CD4 or CD8 and are termed double negative cells (DNs). DN thymocytes can be divided into four sequential phenotypic stages (DN1, DN2, DN3  and  DN4),  which  are  defined  by  different  expression  levels  of  CD44  and CD25  [3].  During  all  DN  stages,  thymocytes  proliferate,  expand  and  migrate through  the  outer  cortex,  where  they  interact  with  cortical  thymic  epithelial cells.  T  lineage  commitment  occurs  during  the  DN2  stage  and  is  largely dependent  on  Notch1  signaling  as  well  as  other  transcription  factors.  The rearrangement of the variable V, D and J gene segments of the TCR β‐chain locus occurs  within  the  DN3  stage.  Because  recombination  activating  gene  (Rag)‐mediated  recombination  often  leads  to  rearrangements  that  are  out  of  frame, cells have to pass a checkpoint called β‐selection. In order to survive, thymocytes need to express a  functional pre‐TCR consisting of a properly rearranged TCRβ chain, CD3 and the invariant pre‐Tα‐chain. Cell death will be induced in cells that fail to successfully rearrange their TCRβ locus. Thymocytes that pass β‐selection will enter another proliferative burst before they initiate the expression of both CD4 and CD8, thus entering the double positive (DP) stage. DPs rearrange the V and  J  segments  of  the  TCRα‐chain  and  consequently  undergo  the  next checkpoint:  positive  selection.  During  positive  selection,  the  fully  rearranged 
α/β‐TCR is examined for its capability to interact with major histocompatibility complexes  (MHCs).  Only  thymocytes  that  bind  MHC/antigen  complexes  with adequate  affinity will  receive  further  survival  signals.  Thymocytes  that  do  not recognize MHC/antigen complexes will die through apoptosis (death by neglect). Approximately 5‐10% of DPs will survive positive selection [4, 5]. Furthermore, the process of positive selection will determine the lineage of the T cell. DPs that are positively selected on MHCII complexes will become CD4+ T cells, while DPs recognizing  antigens  on MHCI  complexes will mature  into  CD8+  T  cells.  Single positive  (SP)  thymocytes will  now migrate  to  the medulla, where  they have  to pass another checkpoint before they can be released into the periphery. Because positive  selection  is  based  on  the  random  recombination  of  the  TCR  and  the recognition of self‐antigens presented on MHC complexes, this process bears the 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potential for autoimmune reactions. Therefore, a second process has evolved to prevent  the  maturation  of  T  cells  with  overt  reactivity  towards  self‐antigens, namely negative selection. Here, TCR‐bearing thymocytes with a high affinity for MHC‐self  antigen  complexes  will  undergo  programmed  cell  death.    Medullary thymic epithelial cells (mTECs) play an important role in negative selection. They express and present multiple peripheral antigens to the developing thymocytes, a process that depends on the transcription factor autoimmune regulator (AIRE). Negative  selection  is  an  important  component  of  immunological  tolerance  and aims  to  prevent  the  formation  of  auto‐reactive  T  cells  that  could  potentially induce autoimmunity. However, this selection process is not 100% complete and some  auto‐reactive  thymocytes  will  exit  the  thymus  as  mature  T  cells. Consequently  other  mechanisms  of  tolerance  induction  have  been  established and will be discussed later on.  
                                
Figure 1: T cell development and selection (adapted from [6]). T cell progenitors enter the thymus at the cortico‐medullary junction (a). DN thymocytes migrate through the outer cortex. During that process they interact with cortical epithelial cells, undergo β‐selection and mature to DP  thymocytes  (b  and  c).  DPs  undergo  positive  selection  and  T  cell  lineage  commitment  (d), before  they  migrate  as  SPs  into  the  thymic  medulla  (e).  There,  SPs  interact  with  medullary epithelial cells and undergo negative selection (f), before they leave the thymus as mature T cells 
(g). 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SECONDARY LYMPHOID TISSUES   A human body has one spleen, approximated 500‐700 lymph nodes (LNs), many of them hardly visible, and around 30 Peyer`s patches (PP). All  these organs as well  as  tonsils,  adenoids  and  nasal‐  or  bronchus‐associated  lymphoid  tissues (NALT or BALT) belong to the category of secondary lymphoid tissues (SLTs) [7]. SLTs enhance the efficiency of  immune responses by arranging B and T cells  in anatomical  locations  that  favor  their  interaction  with  antigen‐presenting  cells (APCs). Furthermore, they provide a framework, which allows rapid circulation of naïve cells through a location where antigens are concentrated [8]. The spleen consists of a white pulp and a red pulp, both executing very distinct functions.  The  white  pulp  is  composed  of  lymphoid  follicles  that  are  rich  in B cells and periarteriolar lymphoid sheaths, in which mainly T cells are located. The  red pulp  is  responsible  for  clearing  the body  from senescent erythrocytes, particles,  certain  encapsulated  bacteria  and  protozoa.  The  marginal  zone separates  the  red and  the white pulp. The  spleen drains predominantly blood‐borne antigens, which are picked up by professional APCs  that  in  turn activate humoral and cell‐mediated immune responses.   LNs are located at vascular junctions and are connected to lymphatic vessels that deliver antigens and APCs. They consist of a cortex and a medulla (Figure 2 A). B cells  are  mainly  arranged  in  follicles  within  the  outer  cortex  and  have  the potential, as  in the spleen,  to  form germinal centers (GC). GCs are structures  in which B cell affinity maturation and antibody class switch takes place. T cells are predominantly  located  within  the  inner  cortex.  Antibody‐secreting  B cells (plasma  cells)  can  be  found  within  the  medulla.  LNs  are  connected  to  the lymphatic  system  and  filter  lymph  rather  than  blood.  The  lymph  delivers antigens and APCs that sample antigens in peripheral tissues to the node.  PPs are aggregations of follicles populated by B and T cells that bulge into the gut lumen.  PPs  are  not  connected  to  afferent  lymphatics  and  obtain  their  antigens from the lumen of the mucosa via so‐called microfold (M) cells [9].  The function of PPs is the immuno‐surveillance of the intestinal lumen.  





(A) The main structural components of lymph nodes are shown. (B) Lymphoid neogenesis upon chronic inflammation leads to tertiary lymphoid tissues.                                                 T CELL ACTIVATION AND POLARIZATION   Naïve T cells circulate through SLTs to scan for MHC complexes that present the antigen specific for their TCR. Professional APCs, such as macrophages and DCs, are innate immune cells that are activated by microbial components via pattern‐recognition  receptors  (PRRs)  e.g.  Toll‐like  receptors  (TLRs).  The  T  cell  must acquire  three  signals  provided  by  the  APC  in  order  to  become  sufficiently activated  (Figure  3).  The  first  signal  is  the  recognition  of  the  MHC/antigen complex  by  the  antigen‐specific  TCR.  The  second  signal  stabilizes  the immunologic  synapse  via  recruitment  of  co‐stimulatory  adhesion  molecules present on both APC and T  cell,  e.g. CD80/CD86 on APCs and CD28 on T  cells.  The third signal is comprised via the secretion of cytokines by APCs, which signal via  cytokine  receptors  on  T  cells.  These  cytokines  polarize  T  cells  toward  a certain  effector phenotype  [11].  The  activation of  an  antigen‐specific T  cell  via these three signals leads to its massive clonal expansion and a differential gene expression that will result in various T cell phenotypes. 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Figure 3: The 3 signals required for T cell activation (adapted from [11]). Signal 1 consists of  the  binding  of  the  TCR  to  the MHC/antigen  complex. Signal  2  stabilizes  the  immunological synapse by binding of the co‐stimulatory molecules CD80/CD86 to CD28. Signal 3 polarizes the T cell into a specific T cell phenotype via the secretion of specific cytokines by the APC.  
 
 In 1986 CD4+ helper T cells were divided into two independent subtypes, namely Th1 and Th2 cells [12]. While the pro‐inflammatory cytokines interleukin‐12 (Il‐12)  and  interferon  gamma  (IFNγ)  lead  to  the  differentiation  of  Th1  cells  that express  the  transcription  factor  Tbet,  Il‐4  induces  the  polarization  of  GATA3‐expressing  Th2  cells.  Th1  cells  secrete  Il‐2,  TNFα  and  large  amounts  of  IFNγ. They  are  responsible  for  CMI,  defense  against  intracellular  pathogens  and promote  the  differentiation  of  cytotoxic  CD8+  T  cells.  IFNγ  enhances  the phagocytic activity of macrophages and further up‐regulates MHCII molecules on APCs. On the other hand, Th2 cells produce mainly Il‐4, Il‐5, Il‐10 and Il‐13. They stimulate  humoral  immunity  by  aiding  B  cell  activation  and  antibody  class switch. Th2 cells mediate allergic reactions and anti‐helminth responses.  Within the last decade many additional CD4+ T cell subtypes have been described (Figure 4)  [13, 14]. Thymus‐derived, natural  regulatory T  cells  (nTregs)  express the  transcription  factor  forkhead  box  P3  (FoxP3)  and  secrete  transforming growth  factor beta  (TGF‐β),  Il‐10 and  Il‐35.  In  the periphery,  regulatory T cells that  also  express  FoxP3  can  be  induced  (iTregs)  in  the  presence  of  TGF‐β  or retinoic acid (RA). A third population of regulatory T cells (Tr1), though they lack the  expression  of  FoxP3  but  produce  high  quantities  of  Il‐10,  has  also  been described [15]. Follicular helper T cells (TFH) can develop in the presence of Il‐6 and  Il‐21  [16].  Another  T  helper  subtype  that  was  recently  described  and strongly  associated  with  different  autoimmune  diseases  is  the  Th17  lineage. Th17 cells are induced by TGF‐β, Il‐6 and Il‐23 and secrete Il‐17A, Il‐17F and Il‐
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22  and  express  the  transcription  factor  retinoic  acid‐related  orphan  receptor gammat  (RORγt)  [17,  18]. A  combination of  Il‐4  and TGF‐β  has been  shown  to induce CD4+ T cells  that secrete  Il‐9, and  these cells have recently been named Th9 cells [19, 20].   
 
Figure 4: T helper  cell  differentiation  and plasticity,  adapted  from  [14].  (A) The  classical monolithic view  is based on  the original  idea  that T cell  subsets behave  like  inflexible  lineages with  the expression of  lineage‐defining  transcription  factors and a certain cytokine profile. (B) Recent  studies  revealed  that T  cell  lineages  are  flexible  and  can be  converted  into other T  cell subsets dependent on the present cytokine microenvironment. In the process of plasticity, T cell subsets  can  change  their  cytokine  profile  and  the  expression  of  master  regulators  and transcription factors.  
 
 Classically,  these  CD4+  T  cell  subsets  have  been  thought  to  be  stable  T  cell lineages characterized by the expression of a certain cytokine profile as well as their master transcription factors (Figure 4A). Recent studies suggest, that T cell phenotypes are more plastic than once thought (Figure 4B). For example TGF‐β has  been  shown  to  reprogram  Th2  cells  by  repressing  GATA3  and  Il‐4,  but inducing the production of Il‐9 [19]. Tregs can be converted to Th17 cells and into IFNγ‐producing cells. Th17 cells in the absence of TGF‐β and in the presence of Il‐12 can transit into Th1 cells [21]. One recent report has demonstrated that Th17 cells,  that develop  in  the absence of TGF‐β  but  in  the presence of  Il‐23 mature into autoimmune pathogenic T cells that express both transcription factors Tbet and RORγt [22]. The accumulation of data describing evidence for T cell plasticity revolutionizes our understanding of the different T cell subsets. 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TERTIARY LYMPHOID TISSUES    As shown above, PLTs and SLTs are clearly defined organs. Their location within the body is determined during ontogenesis. In contrast, tertiary lymphoid tissues (TLTs)  are not  genetically  fixed and  lack  a  capsule.  They often  show  lymphoid tissue‐specific  organization  with  T  cell  zones  and  B  cell  follicles  that  contain follicular  dendritic  cells  (FDCs)  (Figure  2B).  TLTs  develop  ectopically  and  are induced  by  chronic  inflammation,  autoimmunity  or  chronic  graft  rejection  [7]. The  neogenesis  of  TLTs  has  been  observed  in  several  organs:  lungs,  joints, thyroid, liver and CNS to only name a few [23].    
SELF TOLERANCE AND AUTOIMMUNITY   The  activation  of  the  antigen‐specific  (adaptive)  immune  system  is  initiated within SLTs or TLTs by the recognition of antigens in association with so‐called “danger signals”.  These danger signals are usually components of invaders such as bacteria, parasites, worms or viruses that signal our body an infection or the like. Followed by that, antigen‐specific activation of either T or B cells will lead to clearance of the pathogen. If immune cells within a healthy body recognize their antigen in the absence of danger signals, tolerance is induced. Therewith, one of the main  principles  of  the  adaptive  immune  system  is  to  tolerate  self‐antigens (components  of  our  body)  and  only  attack  when  the  body  is  challenged  by pathogens.  Immunological  tolerance  comprises  two  different  mechanisms, namely  central  tolerance  and  peripheral  tolerance.  In  central  tolerance, developing lymphocytes (T cells in the thymus and B cells in the bone marrow) are scanned for their auto‐reactivity early during development and consequently eliminated  via  apoptosis.    Peripheral  tolerance  can  be  induced  on  different levels: via anergy, deletion or suppression by regulatory T cells [24]. 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Autoimmunity  is  defined  as  a  failure  of  the  immune  system  to  tolerate  self­antigens of the body. The immune system recognizes self‐antigens of the body as 
foreign, which leads to an attack of cells and whole tissues. How this “confusion” of the immune system to discriminate self from foreign is initiated, is up to today poorly understood. Possible triggers are molecular mimicry by viral components or environmental factors. Autoimmune diseases affect approximately 5% of the population  in  industrial  countries.  Prominent  examples  are  systemic  lupus erythematosus,  rheumatoid  arthritis,  Crohn`s  disease,  diabetes mellitus  type 1, psoriasis, ulcerative colitis and multiple sclerosis [25]. In this thesis, a model of T cell‐driven encephalomyelitis that resembles clinical aspects  of  multiple  sclerosis  is  used  in  several  experimental  setups.  The following chapter will  introduce this autoimmune disease and its animal model in more detail.   MULTIPLE SCLEROSIS  
PATHOLOGY AND SYMPTOMS  Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS),  which  is  often  progressive  and  results  in  neurological  damage  and disability [26]. MS is considered a classical T cell‐mediated autoimmune disease, that leads to degenerative processes including inflammatory injury of axons and glia, diffuse damage to white matter and involvement of both deep and cortical gray matter [27]. A hallmark of MS is the formation of lesions and plaques within the white matter. These are generally areas of inflammation, demyelination and gliosis.  Myelin  and  oligodendrocyte  auto‐reactive  T cells  release  toxic inflammatory mediators within  the  brain  that  result  in  axonal  and  glial  injury. This inflammation in turn leads to the activation of astrocytes and the release of growth factors that encourage remyelination and partly functional recovery. The neurological  symptoms  lead  to  both  physical  and  cognitive  disabilities  [26]. Physical  disabilities  include  general motor  impairments,  tremor,  poor  balance, stiffness,  painful  spasm,  and  impaired  speech  and  swallowing.  Cognitive impairments  appear  in  deficits  in  attention,  reasoning  and  fatigue.  The  most 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common  form  of  the  disease  is  the  relapsing‐remitting  MS,  which  is characterized by phases of immune attack and destruction that are followed by phases of remyelination and recovery. Relapsing‐remitting MS can develop into a secondary progressive MS. A small percentage of patients experience a  form of the  disease  known  as  primary  progressive  MS,  where  no  phases  of  recovery occur.  
EPIDEMIOLOGY 
 MS  affects  around  2 million  people  worldwide  and  is  the  most  common  non‐traumatic, disabling neurological disease of young adults  [28]. Areas displaying the highest levels of prevalence are northern and central Europe, northern USA, Canada,  southeastern  Australia,  the  former  Soviet  Union  and  New  Zealand, suggesting  that  environmental  factors  found  pre‐dominantly  within  industrial countries might partly trigger the disease [29, 30].  
RISK FACTORS  MS  results  from  the  interplay  between  yet  unidentified  environmental  factors and susceptibility genes. The most prominent association of genetic risk and MS has been described  for human  leukocyte antigen (HLA) class  II molecules  [31]. HLA  types  positively  or  negatively  associated  with  the  disease  are  region‐specific. The two HLA‐DRB genes of the HLA‐DR15 haplotype confer the largest part of genetic risk  in Caucasians of Western Europeans [32]. Also other genes, though with more modest  effects,  have  been  associated with  susceptibility  for the disease, such as  interleukin‐7 receptor α  (Il‐7RA) and Il‐2RA, C‐type  lectin‐domain family 16 member A (CLEC16A), CD58, tumour‐necrosis‐factor receptor superfamily member 1A (TNFRSF1A),  interferon regulatory factor 8 (IRF8) and CD6 [33]. Furthermore, ethnic origin, most likely based on genetic determinants, has been associated with disease susceptibility. Curiously, the disease is virtually absent  in  Chinese  and Filipinos  [34].  Although MS  is more  common  in women than  in men  (2:1)  [35], no disease‐related genes have been  identified on  the X 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chromosome,  which  suggests  that  the  sex‐related  preference  of  MS  might  be associated with female‐specific physiology (e.g. hormones) [36].  Environmental  risk  factors  associated  with  the  disease  include  Epstein‐Barr virus (EBV), smoking and vitamin D [31]. Although EBV is a ubiquitously latent infection  of  our  population  with  94%  incidence,  99%  of  MS  patients  are  EBV positive  [37].  People  that  have  experienced  infectious  mononucleosis  have  an increased  risk  to  develop  MS  as  well  as  people  with  high  titers  of  anti‐EBV antibodies [38].   
THERAPIES  Most  therapeutical approaches aim at disabling  the  immune system, which can be achieved in several ways: (i) Whole immune cell populations, that are thought to  be  involved  in  the  pathogenicity,  can  be  targeted.  (ii)  The  migration  of lymphocytes  from  the  periphery  to  the  CNS  can  be  blocked.  Alternatively,  (iii) the most direct approach lies in ”resetting” the immune system by wiping out the existing immune repertoire (including auto‐reactive cells) and allowing a healthy immune system to regenerate [28]. The drawback of all  these strategies  is  that they also deplete “normally” functional immune cells and therewith compromise general immune protection.  The  following paragraph will briefly  summarize current drugs  that are used  in MS treatment: 
Glatiramer acetate (GA) is a heterogenous mixture of proteins and polypeptides that acts as an altered peptide ligand for myelin basic protein [39]. The induced GA‐specific T cell clones tend to express predominantly a Th2 phenotype, which produces  anti‐inflammatory  cytokines  such  as  Il‐4,  Il‐10  and TGF‐β.  These GA‐specific Th2 cells can then be found within the CNS of MS patients, presumably causing a phenomenon known as  “bystander suppression” of  inflammation. GA furthermore also  exhibits neuroprotective  activity by  inducing  the  secretion of neurotrophic  factors  such  as  brain‐derived  neurotrophic  factor  (BDNF)  and neurotrophin 3 and 4 in the brain. 
Interferon­beta is one of the oldest and most classical treatments in MS [40]. Like GA,  it  belongs  to  a  drug  category  that  exerts  anti‐inflammatory  and  immuno‐
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modulatory effects.  Interferon‐beta  inhibits MS disease activity by on one hand inhibiting  pro‐inflammatory  cytokines,  nitric  oxide  synthase,  T  cell  activation and  migration  and  on  the  other  hand  stimulating  the  production  of  anti‐inflammatory cytokines such as Il‐10 and Il‐4. 
Natalizumab  is  a  humanized  IgG4  monoclonal  antibody  that  binds  very  late antigen‐4  (VLA‐4).  VLA‐4  is  an  adhesion  molecule  expressed  on  lymphocytes that binds to vascular cell adhesion molecule‐1 (VCAM‐1), which is expressed by cerebrovascular  endothelial  cells.  It  mediates  the  migration  of  lymphocytes through  the  blood‐brain  barrier  (BBB)  into  the  CNS.  Blocking  this  process prevents the infiltration of the CNS with auto‐reactive immune cells. 
Fingolimod  (FTY720)  acts  as  a  super‐agonist  to  the  sphingosine‐1‐phosphate receptor  (S1PR),  which  is  expressed  by  lymphocytes  and  mediates  their migration  into  and  out  of  SLTs.  Blocking  this  interaction  leads  to  the sequestering of lymphocytes within SLTs and prevents the migration to the CNS.  
Daclizumab is a humanized IgG1 antibody that binds CD25. The intention of this drug was to specifically target activated T cells. However, Daclizumab was shown to  expand  a  subset  of  NK  cells  that  express  high  levels  of  CD56  and  state immuno‐regulatory properties by inhibiting the survival of activated T cells [41].  
Rituximab  is  a  chimeric  murine/human  IgG1k  CD20‐specific  antibody,  which triggers  cytolysis  in pre‐B  cells.  The  success of  a phase  II  trial  using  rituximab supports  the  idea  that  B  cells  play  a  role  in  the  pathology  of  the  disease. However,  because  rituximab does not  target plasma  cells,  it  is  unlikely  that  its effect is conducted via the reduction of pathogenic autoantibodies but rather by modulating  antigen‐presentation  and  cytokine  production  that  regulate  T  cell responses [42].  
Alemtuzumab (Campath­1H) is a humanized anti‐CD52 antibody, which leads to massive  lymphopenia,  and  disables  the  immune  response  by  simply  removing lymphocytes. CD52  is expressed on the surface of  lymphocytes and monocytes, but its function is unknown. After treatment, CD4+ T cells need up to 5 years to recover to pre‐treatment levels. Alemtuzumab is also used as treatment for other disease,  such  as  chronic  lymphocytic  leukemia,  renal  transplantation  and  a variety of other autoimmune diseases [43‐45]. 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Cladribine  (2‐chlorodeoxyadenosine)  is  an  adenosine  deaminase‐resistant nucleoside analogue with selective lymphotoxicity. It incorporates into the DNA, causing  DNA  damage  and  cell  death.  It  thereby  follows  the  principle  of 
alemtuzumab treatment by inducing lymphopenia.   EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS (EAE)   EAE was established over 50 years  ago  [46].  It  is used as  an animal model  for autoimmune  inflammation  of  the  CNS,  which  resembles  many  characteristics also  observed  in  MS.  EAE  is  a  T  cell‐driven  autoimmune  disease  and  can  be induced by subcutaneous (s.c.) immunization of animals with myelin proteins or antigens  that  are  emulsified  in  complete  Freund`s  adjuvant  (CFA).  Myelin proteins/antigens  used  for  immunization  are  e.g.  myelin  basic  protein  (MBP), proteolipid  protein  (PLP)  or  myelin  oligodendrocyte  glycoprotein  (MOG). Furthermore, the animals are treated with pertussis toxin (PTx), which has been shown  to  facilitate  the  migration  of  immune  cells  into  the  brain.  PTx  also contributes  to  breaking  T  cell  tolerance  and  promoting  clonal  expansion  and cytokine production by T cells [47, 48]. In murine EAE, the disease manifests by the paralysis of tail and hind limbs, which then progresses to the forelimbs. The area  of  inflammation  is mostly  targeted  to  the  spinal  cord  and  the  cerebellum [49].  Besides active immunization with myelin proteins, EAE can also be induced via different  strategies.  Classical  passive  immunization  is  based  on  the  adoptive transfer  of  previously  activated  myelin‐specific  CD4+  T  cells  into  naïve  mice. Alternatively, also the adoptive transfer of MOG‐ or MBP‐specific CD8+ T cells can mediate severe CNS autoimmunity [50, 51]. Certain virus models are capable of inducing encephalomyelitis and are therefore useful  tools  in understanding the potential  viral  etiology  of  MS.  The  exposure  to  Theiler`s  murine encephalomyelitis virus (TMEV) can for example lead to fatal encephalomyelitis and  immune‐mediated  demyelination  [52,  53].  Transgenic  mouse  models  that lead  to  the  ablation  of  brain‐specific  cell  types  allow  the  investigation  of demyelinating processes  that  are not  initiated  in  the periphery of  the host but 
      INTRODUCTION                            
  30 
rather within  the CNS. The depletion of oligodendrocytes via a diptheria  toxin‐mediated  cre‐sprecific mouse model  results  in  severe myelin  loss  that  leads  to tremor,  hind  limb  paralysis  and  weight  loss  [54].  Furthermore,  toxin‐based models  like  cuprizone,  lysolecithin,  or  lipoploysaccharide  (LPS)‐injections  into the  brain  are  used  to  study  the  general mechanisms  of  de‐  and  remyelination [55‐57].  Altogether,  these  different models  serve  to  understand  general  aspects  of MS.  However,  there  are  limitations  and  cautiousness  that  have  to  be  kept  when interpreting data coming from animal models. The initial trigger of MS remains to  be  identified.  For  that  reason,  drug  testing  and  clinical  trials  cannot  yet  be replaced by the study of the above‐described models.   We  have  learned  above  that  the  thymus will  eliminate  T  cells  that  carry  TCRs with a high affinity to self‐antigens. However, despite this selection process, self‐reactive  T  cells  can  be  found  in  our  body.  These  ones  need  to  be  tightly controlled  within  the  periphery.  For  instance,  an  auto‐reactive  T  cell  will  be rendered tolerant, if one of the three signals provided by APCs is missing. In the model  of  EAE,  T  cells  are  not  only  presented  with  an  auto‐antigen,  but  an adjuvant  consisting  of  microbiological  components  will  deliver  the  additional danger  signal,  that  activates  APCs  to  provide  all  three  signals  and  therewith breaks tolerance in auto‐reactive T cells. 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NFκB­SIGNALING   Besides  the  structure  of  lymphoid  tissues  and  the  three  activating  signals provided by APCs, all immune cells depend on molecular signaling pathways that allows  them  to  translate  incoming  receptor  signals  into  a  differential  gene expression.  One  of  the  ubiquitous  signaling  cascades  frequently  used  by  all immune  cells  is  the  nuclear  factor  kappa  B  (NFκB)  pathway.  For  the  work presented in this thesis, not only the requirements of SLTs in CMI are of interest, but also molecular requirements,  in particular these of a specific kind of NFκB‐signaling. The following chapter will therefore introduce this signaling cascade in more detail.  NFκB  regulates  genes  that  are  involved  in  various  stages  of  the  immune response  such  as  activation  of  innate  cells  and  lymphocytes,  DC  maturation, inflammation  and  survival.  NFκB  represents  a  family  of  transcription  factors, which in mammals comprises of RelA (p65), RelB, c‐Rel, NFκB1 (p50) and NFκB2 (p52)  [58].  These  are  structurally  homologous  proteins  that  form  homo‐  or heterodimers via their terminal Rel homology domains (RHDs). In unstimulated cells the RHDs of NFκBs associate with inhibitory proteins of κB (IκBs) and are sequestered  in  the  cytoplasm.  Both  NFκB1  and  NFκB2  comprise  of  large precursor  proteins  (p105  and  p100,  respectively)  that  need  to  be  post‐translationally  processed  (to  p50  and  p52,  respectively)  for  their  activation. While p105 processing is constitutive, the processing of p100 is regulated [59]. Most NFκB dimers are activators, although p50/p50 and p52/p52 homodimers are repressive in gene activation. Generally, NFκB can be divided  into  two pathways,  the  canonical  and  the non‐canonical (also classified as classical and alternative, respectively), which will be discussed in more detail below (Figure 5). 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Figure 5: Two NFκB­pathways (adapted by [60]). TNFR family members, Il‐1R and TLRs are inducing canonical NFκB‐signaling, whereas CD40, BAFFR, LTβR and RANK induce non‐canonical NFκB‐signaling.   CANONICAL NFκB‐SIGNALING   Pro‐inflammatory  cytokines  and  pathogen‐associated  molecular  patterns (PAMPs)  cause,  via different  tumor necrosis  factor  receptors  (TNFRs) or TLRs, activation of the IκB kinase complex (IKK). The most prominent IKK complex is the  so‐called  NEMO  complex,  consisting  of  two  catalytic  (IKKα  and  IKKβ)  and one regulatory subunit (IKKγ). The IKK complex catalyzes the phosphorylation of IκB,  its polyubiquitination and subsequent degradation by the 26S proteasome. The  released  NFκB  dimers  translocate  to  the  nucleus  and  activate  gene transcription [61]. 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The  knowledge  obtained  of  the  physiological  function  of  canonical  NFκB‐signaling  stems  largely  from  the  analysis  of  NFκB1‐/‐  mice.  These  mice  show multifocal defects in immune system function [62]. Data from NFκB1‐/‐ mice have revealed  that  the  maturation  and  survival  of  B  cells  as  well  as  the  humoral response to T cell‐dependent antigens depends on NFκB1. CD4+ T cells depend on canonical NFκB‐signaling for their proliferation and up‐regulation of CD25, as well  as  their  functional  maturation  into  different  T  helper  phenotypes. Macrophages  depend  on  NFκB1  for  the  production  of  Il‐6  and  Il‐12  upon encountering  LPS  stimulation.  The  response  and  control  to  certain  infectious organisms  relies  on  canonical  NFκB‐signaling,  including Leishmania major  and 
Streptococcus pneumonia infections [62, 63].    NON‐CANONICAL NFκB‐SIGNALING AND NIK   For  many  years  it  has  been  believed  that  the  non‐canonical  NFĸB‐pathway  is preferably activated by ligands important for either the lymphoid organogenesis (through LTβ) or in B cell responses (through CD40L and BAFFL) [64]. However, it has become increasingly evident that the non‐canonical NFĸB‐pathway can be triggered by many different ligands such as RANK, LIGHT, TWEAK, CD70, CD28, Il‐1 and LPS, thereby playing an important role in various responses [65‐72].  Non‐canonical NFκB‐signaling  is  independent of  IKKβ  and  IKKγ  [73].  Instead  it requires the NFκB‐inducing kinase (NIK) and IKKα to induce the slow processing of  p100  to  p52.  NIK  directly  phosphorylates  and  activates  IKKα.  An  IKKα homodimer  phosphorylates  the  precursor  protein  p100  that  leads  to  its polyubiquitination  and  degradation  to  the  active  form  p52.    Active  p52  most commonly dimerizes with RelB [74].  The activity of NIK is tightly regulated on several levels [75]. In resting cells, NIK is constitutively degraded through ubiquitination by a complex consisting of TNF receptor‐associated  factors  (TRAF)  2  and  TRAF3  and  cytosolic  inhibitor  of apoptosis (cIAP) 1 and cIAP2 [76, 77] thereby preventing basal activation of this pathway  (Figure  6A).  The  signal‐induced  activation  of  the  non‐canonical 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pathway  results  in  the  degradation  of  TRAF2  and  TRAF3,  leading  to  the stabilization  of  NIK  protein  [78].  A  second  control  level  has  recently  been described  for  the  regulation  of  NIK  activity  in  stimulated  cells where NIK  and IKKα  form  a  specific  kinase  complex,  in  which  NIK  phosphorylates  IKKα  and recruits  it  to  p100  [79].  In  that  process  IKKα  also  phosphorylates  NIK  and targets  it  for  degradation  [80],  thereby  controlling  the  magnitude  of  NIK accumulation via a negative‐feedback mechanism (Figure 6B).   
                     
Figure 6: Regulation of NIK activity (adapted by [75]).  (A)  In unstimulated cells,  cIAP1 and cIAP 2 constantly target NIK for ubiquitination and degradation via interaction with TRAF2 and TRAF3. (B) Upon activation, TRAF 2 and TRAF 3 are targeted for cIAP‐mediated ubiquitination and  degradation  by  the  stimulated  receptor  complex.    NIK  is  released  and  stabilized  and  can activate IKKα, which triggers the processing of p100. In turn, activated IKKα phosphorylates and induces the degradation of NIK to prevent an overaccumulation of NIK in activated cells.    There  is  evidence  that  NIK  also  signals  into  the  classical  NFκB‐pathway.  For example,  CD40,  BAFF  and  CD27‐signaling  depend  on  NIK  for  the  activation  of both  pathways  [67].  Also  the  inhibition  of  TRAF3,  the  essential  negative regulator  of  the  non‐canonical  pathway,  results  in  activation  of  both  canonical and non‐canonical signaling cascades [81]. A recent report describes that LTβR‐induced  signaling  via  NIK  can  result  in  the  phosphorylation  of  p65,  which together with RelB synergistically enhances the gene expression of granulocyte‐
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macrophage stimulating factor (GM‐CSF), a cytokine that is produced by T cells and plays a role in DC development [82]. These reports challenge the prevailing wisdom of two distinct NFĸB‐pathways and it is important to further investigate the circumstances under which this cross‐talk can occur.  NFκB AND NIK PLAY A ROLE IN VARIOUS DISEASES   NFκB  plays  an  important  role  in  the  initiation  and  promotion  of  cancer  by fostering  an  inflammatory  milieu  in  which  various  cytokines  aid  and  abet malignant  transformation  [83].    Deregulated  activation  of NFκB  contributes  to diseases that range from chronic inflammation and autoimmunity to cancer [84‐86]. In a variety of lymphoid cancers, NFκB is constitutively active due to diverse somatic mutations,  genomic  amplifications or  chromosomal  translocations.  For example, mucosa‐associated lymphoid tissue (MALT) lymphoma can be induced by  a  genetic  translocation  that  leads  to  a  fusion  protein  of  cIAP2  and  MALT, which stabilizes the activation of the canonical NFκB‐pathway. Mutations in NIK that  interrupt  the TRAF3‐binding domain  can  cause highly  stable NIK proteins that have been associated with the development of multiple myeloma [87]. Also high‐level amplifications of  the NIK genomic  locus and NIK gene translocations that  lead  to  overexpression,  as  well  as  TRAF3  gene  deletions  or  deletions affecting  the  closely  linked  cIAP1  and  cIAP2  have  been  identified  in  multiple myeloma [83, 85]. Chronic activation of NFκB due to persistent viral infection can also promote the progression to malignancies [88]. The latent membrane protein 1 (LMP1) of EBV can induce NIK‐dependent p100 processing that has been associated with EBV‐positive  Hodgekin`s  lymphoma  [89‐91].  The  Kaposi  Sarcoma‐associated herpesvirus  (KSHV)  can  induce  primary  effusion  lymphoma  through  the  viral protein vFLIP that can lead to IKK activation. The human T cell lymphoma virus (HTLV) expresses the tax oncoprotein that binds to NEMO and thereby induces IKK  activation  or  alternatively  activates  the  IKKα‐dependent  non‐canonical NFκB‐pathway [85]. 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Although  the  contribution  of NFĸB‐signaling  seems  to mainly  add  to  lymphoid malignancies, there is evidence that the transformation of solid cancers, such as breast cancer, is effected by dysregulated NFĸB [92].  Taken together, NIK poses an attractive pharmacological target for the treatment of  a  variety  of  diseases  [83]  and  it  is  thus  important  that  its  role  and  function within the immune system is resolved.   
ALYMPHOPLASIA MICE   As  mentioned  above,  non‐canonical  NFĸB‐signaling  is  a  prerequisite  for  the 
anlage  of  SLTs.  Mice  carrying  lesions  in  elements  of  this  pathway  are  often alymphoplastic (absence of LNs) and lack the specific  lymphoid organization in spleen  and  thymus  [74,  93].  As  a  result  these  mice  become  highly  immuno‐deficient.  Due  to  their  inability  to  generate  GCs,  alymphoplastic  mice  such  as LTβR‐/‐,  LTα‐/‐, NIKaly/aly  or NIK‐/‐  are all defective  in  immunoglobulin  (Ig)  class switch and hypermutation [94‐97]. One of the most widely used mouse strains for studying the role of SLTs during immune  responses  is  the alymphoplasia  (NIKaly/aly)  strain, which  carries  a  NIK point  mutation.  The  mutation  in  NIKaly/aly  mice  was  originally  found  as  a spontaneous autosomal recessive mutation  that  leads  to  the absence of all LNs and PPs.   NIKaly/aly spleens are devoid of well defined lymphoid follicles and the white  pulp  is  atrophic  [94].  The  NIK  mutation  in  NIKaly/aly  mice  lies  in  the  C‐terminal  region  (G855R  substitution  [98]),  which  is  responsible  for  physical interaction with the upstream TRAFs and IKKα [99]. Hence, the NIKaly/aly kinase domain  is still  intact and capable  to  induce NFκB activation, but due to  lacking upstream signaling the levels of nuclear p52 in several tissues and cell types are virtually ablated [59].  NIKaly/aly  mice  display  impaired  antibody  responses  and  loss  of  CMI, demonstrated  by  their  inability  to  reject  allogeneic  grafts  or  tumors  [99‐101]. IgM levels in NIKaly/aly mice are one‐third of these found in heterozygote animals, and IgG and IgA are virtually absent [94]. NIKaly/aly T cells have been shown to be defective  in secretion of  Il‐2 and GM‐CSF [70]. They are  limited in proliferation 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and  Th17  differentiation  and  fail  to  become  pathogenic  in  EAE  or  in transplantation models [70, 102‐107].  Summarized,  NIKaly/aly  mice  show  several  deficiencies  in  humoral  and  cell‐mediated immune responses. These deficiencies have been largely explained by their lack of SLTs. However, the fact that NFĸB‐signaling plays a role in virtually all aspects of immunity presents another explanation for the immunodeficiency in NIKaly/aly mice that have partly disrupted NFĸB‐signaling. This possibility was strongly  ignored  in  previous  research.  We  observed  that  NIKaly/aly  mice  are resistant  to  the  induction of T cell‐mediated EAE. That  finding renders  the LN‐less  NIKaly/aly  mice  a  very  interesting  tool,  in  which  we  disconnected  the  two pathways of disrupted SLTs and lesioned NIK‐signaling, in order to study on one hand the requirements of SLTs and on the other hand the requirement of NIK‐signaling in CMI. 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SPECIFIC AIMS    For a  long time,  the  immunodeficiency of NIKaly/aly mice was attributed to  their lack of LNs and absent organization in spleen, as these structures are believed to be  absolutely  essential  for  the  induction  of  adaptive  immunity.  However,  the possibility that the immunodeficiency of NIKaly/aly mice is caused by the intrinsic lesion of NIK has been neglected.  In  this  thesis,  I  therefore  aimed  to  dissect  the  cause  of  NIKaly/aly immunodeficiency by defining the following objectives:     (a)   Assess the structural requirements for efficient humoral and cell‐mediated immunity and the development of autoimmunity.   (b)  Define the role of NIK‐signaling in cell‐mediated immunity. 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CELL­MEDIATED IMMUNITY   Greter M1*, Hofmann J1*, Becher B1 PLoS Biol. 2009 May 5;7(5)  1 Institute of Experimental Immunology, University Zürich, Switzerland * These authors contributed equally to this work.   In this study, we describe that the immunodeficiency of NIKaly/aly mice is not due to the absence of SLTs, but due to the impact of the underlying genetic defect on cellular  immunity.  Using  different  strains  of  alymphoplastic  mice  and  T‐cell migration mutants, in an experimental paradigm in which the site of Ag‐delivery is  distant  from  the  site  of  priming  and  again  distant  from  the  site  of inflammation, we can detect both Th cell‐driven autoimmune disease as well as systemic  CTL‐mediated  anti‐tumor  immunity  initiated  through  classical subcutaneous  (s.c.)  immunization/vaccination  independent  of  SLTs.  APCs present at  the site of  immunization migrate  to and select  the  liver as a natural extra‐lymphoid  tissue  for  the  initiation  of  CMI,  which  we  propose  to  be  an evolutionary  hard‐wired  pathway  already  found  in  cold‐blooded  vertebrates. This,  to  this  day  undescribed  alternative  pathway,  can  potently  drive  CMI  but fails  to  elicit  B  cell  immunity,  indicating  that  the  immunization‐induced  T  cell accumulation  within  conventional  lymphoid  organs  mainly  serves  humoral immunity but that CMI can be initiated elsewhere. 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AUTOIMMUNITY CANNOT BE INITIATED IN NIKALY/ALY MICE   We first sought  to determine whether LNs are an absolute requirement  for  the induction of a complex Th cell‐driven autoimmune response initiated by the s.c. delivery  of  auto‐antigen  (Ag).  EAE  is  a  B  cell‐independent,  TH  cell‐mediated demyelinating autoimmune disease of  the CNS and serves as  the animal model for  MS.  The  conversion  of  TH  cells  from  the  naïve  to  effector  state  is  vitally dependent on the structures provided by LNs [108, 109]. Cervical LNs are widely held to constitute the predominant intrinsic priming site for encephalitogenic T cells, based on the observation that these LNs support the expansion of PLP‐TcR Tg  T  cells  [110,  111].  However,  draining  inguinal  LNs  drive  the  polyclonal, endogenous  T  cell  population  after  s.c.  immunization  with  encephalitogenic peptides. To assess the role of SLTs in the transition of TH cells from a naïve to effector state (T cell priming), we induced EAE in NIKaly/aly or NIKaly/+ mice by s.c. immunization with MOG peptide and complete Freund adjuvant (MOG35‐55/CFA). Fig. 7A  shows  that NIKaly/aly mice are  completely  resistant  to EAE compared  to NIKaly/+  control  mice  (the  latter  developing  normal  SLTs  as  NIK  is  haplo‐sufficient).  To  verify  the  notion  that  pathogenic  T  cells  cannot  be  raised  in NIKaly/aly mice, they were immunized s.c. with MOG35‐55. 11 dpi, splenocytes were harvested,  MOG35‐55‐reactive  cells  were  expanded  in  vitro  and  subsequently transferred  into NIKaly/aly  as well  as NIKaly/+  recipients.  Fig.  7B  shows  that only cells  derived  from  NIKaly/+  donors  were  able  to  induce  disease  regardless whether the recipients had SLTs (NIKaly/+) or not (NIKaly/aly). In contrast, MOG35‐55‐reactive T cells derived from NIKaly/aly donors were not pathogenic and did not mediate CNS‐inflammation. 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Figure 7. NIKaly/aly mice are  resistant  to  the development of EAE.  (A)  EAE was  induced by active  immunization  with  MOG35‐55/CFA  in  NIKaly/aly  ()  and  NIKaly/+  mice  ().  (B)  EAE  was induced  by  adoptive  transfer  of  pathogenic  T  cells  derived  from MOG‐immunized  NIKaly/aly  or NIKaly/+ donors into NIKaly/aly or NIKaly/+ recipients. NIKaly/+ into NIKaly/+: ▲, NIKaly/+ into NIKaly/aly: Δ, NIKaly/aly into NIKaly/+: ●, NIKaly/aly into NIKaly/aly: ○. Shown is a representative of two individual experiments (n ≥ 5 mice/group). (C) NIKaly/+  and NIKaly/aly mice were injected with 20x106 CFSE‐labeled splenocytes i.v. derived from 2D2 transgenic mice and immunized s.c. with MOG35‐55/CFA. 4  dpi  splenocytes  were  analyzed  by  flow  cytometry  by  gating  on  2D2+  cells.  Results  are representative of 2 individual experiments (n = 2 mice/group).  To assess the capacity of LN‐less mice to initiate T cell expansion in response to s.c.  delivered  Ag,  CFSE‐labeled  TCR  transgenic  T  cells  (2D2)  specific  for  the encephalitogenic MOG35‐55 peptide [112] were adoptively transferred into either NIKaly/aly  or NIKaly/+ mice  prior  to  immunization with  their  cognate  Ag.  After  4 days, splenocytes were analyzed for T cell expansion by flow cytometry (Fig. 7C). Ag‐specific T cell proliferation can be observed in NIKaly/aly mice, however, they display slightly delayed kinetics  in comparison to NIKaly/+ mice.   Similar results were obtained with Ovalbumin (OVA) TCR transgenic T cells (OTII) transferred into NIKaly/aly and NIKaly/+ mice (not shown), indicating that T cell expansion can be  initiated  independent of  SLTs, while  efficient  effector  function  is dependent on the microenvironment provided by SLTs. 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INDUCTION OF PRODUCTIVE T CELL IMMUNITY IN THE ABSENCE OF SLTS   The  fact  that  NIKaly/aly  mice  do  not  develop  T  cell‐driven  autoimmune  disease could be explained by  their  inability  to prime self‐reactive T cells  i) due  to  the lack of dedicated draining LNs [108, 109], or ii) due to a direct impact of the NIK mutation  on  immune  cells  [105,  106].  In  order  to  define  whether  their  EAE‐resistance  is  due  to  the  lack  of  LNs  or  an  intrinsic  defect  of  NIKaly/aly  mice  to prime  T  cells,  we  generated  a  series  of  bone marrow  (BM)‐chimeric mice.  To restrict the NIK mutation to the hematopoietic system, lethally irradiated NIKaly/+ mice were injected with BM cells from NIKaly/aly donor mice (NIKaly/alyNIKaly/+). Conversely,  to conserve  the developmental  structural defects, without  the NIK‐lesion of the hematopoietic compartment, NIKaly/aly mice were reconstituted with BM cells of normal NIKaly/+ donors (NIKaly/+NIKaly/aly). As previously reported, spontaneous  development  of  lymphoid  tissues  in  NIKaly/aly  recipients  upon reconstitution was expectedly not detected [113]. Surprisingly,  we  discovered  that  NIKaly/+NIKaly/aly  BM‐chimeras  were  fully susceptible  to  EAE  after  s.c.  immunization  with  MOG35‐55  (Fig.  8A),  clearly demonstrating  that  s.c.  immunization  can  mount  a  productive  T  cell‐driven autoimmune response even in the absence of draining LNs. Using the reciprocal approach, by generating NIKaly/+NIKaly/+  (wt‐NIK  immune system and normal SLTs) as well as NIKaly/alyNIKaly/+  BM‐chimeras (NIK‐deficient immune system and normal SLTs), we found that the NIK mutation lead to EAE resistance, even when  the  lymphoreticular  compartment  is  unperturbed  (Fig.  8B).  This  finding clearly demonstrates  that  the  reported  immunodeficiency of NIKaly/aly mice  can largely  be  explained  by  the  requirement  of  NIK  for  the  initiation  of  immunity rather  than  the  lack  of  LNs.  In  support  of  this,  we  found  that  unmanipulated LTβR‐/‐ mice, which also lack all LNs but have normal NIK function, are also fully susceptible to EAE (Fig. 8C). The  formation  of  IFNγ  and  IL‐17‐secreting  auto‐reactive  T  cells  has  been demonstrated to be a prerequisite for the development of autoimmunity [11]. In NIKaly/alyNIKaly/+ mice we observed a  substantial  reduction  in  IL‐17 and  IFNγ producing  cells  compared  to  the  control  mice  NIKaly/+NIKaly/+  (Fig.  8D) 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Figure  8.  SLTs  are  crucial  for  B  but  not  T  cell  mediated  immune  responses.  (A­B)  EAE progression  in  BM‐chimeras  immunized  s.c.  with  MOG35‐55/CFA.  (A)  NIKaly/+   NIKaly/+: ▲, NIKaly/+  NIKaly/aly: ●. (B) NIKaly/aly  NIKaly/+: □, NIKaly/+ NIKaly/+: ▲. (C) EAE was induced by active  immunization  with  MOG35‐55/CFA  of  LTβR‐/‐  mice  (■)  and  wt  mice  (Δ).  Shown  are representatives  of  three  individual  experiments  (n≥5/group) ±SEM.  (D)  LN‐derived  cells were obtained from NIKaly/aly  NIKaly/+ (black bars) and NIKaly/+  NIKaly/+ (grey bars) BM‐chimeras 21  dpi with MOG35‐55/CFA  and  rechallenged  in  vitro with  50  µg/ml MOG35‐55  peptide  to  reveal IFNγ  and  IL‐17  secreting  cells  using  Elispot.  Shown  is  a  representative  of  2  individual experiments  (n=3  /group ±  SEM).  (E) DTH  responses were  induced by  s.c.  immunization with KLH/CFA of NIKaly/aly and NIKaly/+ mice. 11dpi, the mice were challenged by intradermal injection of KLH (grey bars), or PBS (black bars) into the ear. Swelling was measured 24h post challenge using  a  precision  calliper  and  shown  is  the  increase  of  ear  swelling  over  baseline  of  a representative  of  3  independent  experiments  (n  ≥  2  /exp).  (F)  Sera  was  collected  from  KLH‐immunized NIKaly/aly () and NIKaly/+ mice () mice on 12 dpi and analyzed for the presence of total  anti‐KLH  Abs  by  ELISA.  Results  are  representative  of  3  independent  experiments  (n  ≥  2 mice/group). 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B AND T CELLS HAVE DIFFERENT STRUCTURAL REQUIREMENTS FOR PRIMING AND MATURATION   Given  the  dogma  that  in  mammals,  CMI  initiated  by  s.c.  or  intramuscular  Ag‐delivery requires the presence of SLTs, it is feasible that the remaining SLT (i.e. the  spleen)  in NIKaly/+NIKaly/aly  BM‐chimeras  compensates  for  the  absence  of LNs.  In  order  to  test  this  notion,  we  splenectomized  NIKaly/+NIKaly/aly  BM‐chimeras  (NIKaly/+NIKaly/aly  spl)  14  days  prior  to  the  induction  of  EAE.  Upon immunization, NIKaly/+NIKaly/aly  spl mice developed EAE with  the same disease severity as control mice (Table 1). We noted a slight delay in disease onset when all SLTs are absent, while histopathological analysis of diseased mice revealed no difference between NIKaly/+NIKaly/+ and NIKaly/+NIKaly/aly spl mice (Fig. 9). 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Figure 9. Inflammatory lesions in the CNS of mice lacking SLTs. H&E stainings of spinal cord sections  of  diseased  NIKaly/+   NIKaly/+  and  NIKaly/+  NIKaly/aly  spl  BM‐chimeras.  Lower  row represents  higher magnification  of  the  insert  in  upper  row.  Bar  in  upper  row:  200  μm  and  in lower row: 50 μm. In  contrast  to  T  cell  activation,  we  found  that  B  cell  activation  requires  the structural  environment  provided  by  SLTs.  To  investigate  the  impact  of immunization  on  T  vs.  B  cell  responses,  we  used  Keyhole  limpet  hemocyanin (KLH)  as  a  model  foreign  Ag  to  elicit  delayed‐type  hypersensitivity  (DTH) responses. NIKaly/aly  as well  as NIKaly/+ mice were  immunized with KLH and 11 dpi,  they  were  challenged  by  intradermal  injection  with  KLH  into  the  ear.  As illustrated  in  Fig.  8E,  both  groups  were  able  to  mount  a  solid  DTH  reaction measured by ear swelling, which was only marginally lower in NIKaly/aly  than in NIKaly/+ mice.  However,  in  contrast  to  ear‐swelling, which  is  indicative  of  CMI, NIKaly/aly mice did not mount Abs against KLH when compared  to NIKaly/+ mice demonstrating that the development of a humoral immune response is ablated in the  absence  of  lymphoreticular  structures  (Fig.  8F).  We  could  reproduce functional  DTH  responses  using  other  Ags  including  Ovalbumin  and  myelin oligodendrocyte  glycoprotein  peptide  (MOG35‐55)  (not  shown).  Similarly  in  our EAE  paradigm  using  BM‐chimeras,  while  control  mice  (NIKaly/+NIKaly/+  and NIKaly/+NIKaly/+  spl)  elicit  high  Ab  titers,  anti‐MOG Abs  are  virtually  absent  in mice without LNs (either NIKaly/+NIKaly/aly or NIKaly/+NIKaly/aly  spl) (Fig. 10A). 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Analysis  of  isotype  subtypes  revealed  that  in  splenectomized  alymphoplastic mice,  elevated  anti‐MOG  IgM  could  be  detected  which  has  previously  been reported  [114‐116],  while  class  switching  to  IgG  could  not  be  observed  (Fig. 10B). 
Taken together, and  in agreement with  the notion  that SLTs are vital  for B cell activation,  for  the  generation  of  high‐affinity  Igs  and  class  switching,  highly organized  SLTs  are  obligatory,  while  potent  cellular  immunity  can  be  induced successfully upon s.c. immunization even in the absence of SLTs. 
 
Figure  10.  Ab­response  to  s.c.  auto­Ag  depends  on  the  presence  of  dedicated  lymphoid 
structures 
 (A­B) Titers of anti‐MOG Abs (total Ig, IgG, IgM and IgA) determined from sera of diseased BM‐chimeras immunized s.c. with MOG35‐55/CFA by ELISA. NIKaly/+  NIKaly/+: ■, NIKaly/+  NIKaly/+ spl: 
□,  NIKaly/+   NIKaly/aly: ▲,  NIKaly/+   NIKaly/aly  spl:  Δ.  (E)  Total  Ig,  (F)  IgG,  IgM,  IgA.  Shown  is  a representative of 3 individual experiments (n=3 /group ± SEM).  IN THE ABSENCE OF SLTS, SUBCUTANEOUSLY DELIVERED AG IS TRANSPORTED INTO THE LIVER   Since  the  loss  of  SLTs  in  NIKaly/aly  BM‐chimeric  mice  does  not  hinder  the development of T  cell  immunity, we wanted  to determine  at which  alternative site T cell priming could take place and to which organ the Ag travels  from the 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site  of  immunization  (s.c.).  Therefore,  NIKaly/aly  BM‐chimeras were  injected  s.c. with  Yellow  Green  (YG)  carboxylate  microspheres  emulsified  in  CFA.  7  dpi various organs were  isolated and analyzed for the presence of  fluorescent cells by  flow  cytometry.  Fig.  4A  shows  that  in  control  mice  (NIKaly/+NIKaly/+) fluorescently  labeled  APCs  were  exclusively  detected  in  LNs  upon  s.c. immunization. It was previously shown that the BM has the capacity to drive an enriched population of high affinity TCR Tg T cells in response to blood‐borne Ag [117]. As expected, upon i.v. delivery of Ag, the vast majority of it accumulates in the spleen, BM and liver, regardless of the presence of SLTs (Fig. 11). However, after (s.c.) immunization of NIKaly/+NIKaly/aly spl BM‐chimeras lacking SLTs, APCs carrying  fluorescent  microspheres  migrate  primarily  to  the  liver  and  not  the other  organs  analyzed  (thymus,  CNS  &  gut  are  not  shown)  (Fig.  12A).  Only  a small amount of Ag reaches the liver when draining SLTs are present. Next, we wanted to determine the means of the Ag transport from the s.c. reservoir to the liver. To determine whether the Ag diffuses to the liver or is actively transported by  APCs,  NIKaly/+NIKaly/+  and  NIKaly/+NIKaly/aly  spl  chimeric  mice  were separated into two groups. One received YG micropsheres/CFA in the  left  flank and  polychromatic  red  (PR)  microspheres  /CFA  in  the  right  flank.  The  other group received a mixture of YG and PR coupled beads in both flanks (see scheme in  Fig.  12B).  After  7  days,  mice  were  sacrificed,  perfused  and  a  single  cell suspension  of  livers,  LNs  and  spleens  was  generated  for  cytofluorometric analysis. We  found  that  the mixture of PR/YG‐coupled beads generated a  large proportion  of  dual‐labeled  CD11b  as well  as  CD11c  positive  APCs.  Conversely, the  injection of either PR or YG‐coupled microspheres  into each  flank revealed merely  single‐labeled  APCs  in  the  liver.  The  presence  of  single‐labeled  cells within  the  liver  strongly  suggests  that  the  Ag  is  delivered  to  the  liver  by  the migration of APCs initially present at the site of immunization. Passive diffusion of the Ag from the site of immunization via the blood‐stream to the liver cannot be  fully excluded, but  is  evidently not  the dominating means of Ag delivery.  In addition, only a negligible amount of Ag reaches the  liver when dedicated SLTs are present (Fig. 12). We could also confirm these finding by using soluble FITC painted  on  shaved  flanks  (without  the  adjuvant  CFA).  24h  after  FITC+  skin painting, we found FITC+ APCs primarily in the liver again supporting the notion 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Figure 12. Ag­laden APCs migrate to the liver in the absence of SLTs. (A) NIKaly BM‐chimeras were injected s.c. with YG microspheres/CFA and various organs were analyzed by FACS for the presence of fluorescently labeled APCs 7 dpi.  Data represent one of 3 individual experiments. (B) NIKaly BM‐chimeras were  injected  s.c. with  either  a mixture  of  YG  and  PR  beads  (YG+PR)  into both flanks or YG beads into one flank and PR beads into the other flank (YG vs PR). 7 dpi, livers and LNs (only in NIKaly/+  NIKaly/+ mice) were analyzed by FACS for single (YG or PR) or double (YG  and  PR)  positive  APCs  (gated  on  CD11c+  and  CD11b+  cells).  (C)  NIKaly  BM‐chimeras were painted  on  the  shaved  flanks  with  100 µL  of  4 mg/mL  FITC  dissolved  in  1:1 acetone:dibutylphalate.  After  24h,  livers  and  in  NIKaly/+    NIKaly/+  mice  draining  and  non‐draining inguinal LNs were analyzed by FACS for the presence of FITC+ cells.  
  EXTRA‐LYMPHOID AGGREGATES IN THE LIVER HOST T CELL/APC ENCOUNTERS   In  order  to  determine  whether  lymphoid‐like  structures  can  be  found  in  the liver,  we  analyzed  the  livers  of  immunized  mice  by  histology  (d7).  Livers  of NIKaly/+NIKaly/aly  spl BM‐chimeras  showed massive  infiltration of  leukocytes  in comparison  to  NIKaly/+NIKaly/+  control  mice  (Fig.  13).  Histological  analysis displays  dendritic  cells  (DCs)  in  close  proximity  to  T  cells  in  the  infiltrated periportal areas of  the  liver  indicative of T cell priming by Ag‐laden APCs  (Fig. 13B). In spite of the stromas inability to respond to LTα/β, detailed histological analysis revealed the presence of VCAM and ICAM in the infiltrates as well as B cells  (Fig.  14)  and  even  the  presence  of  CXCL13  transcripts  indicative  of aggregates  ability  to  recruit  B  cells  (not  shown). However,  no  evidence  for GC formation could be obtained (Fig. 14). We  also  transferred  TcR  Tg  T  cells  from  Luciferase‐2D2  (Luc‐2D2)  mice  into recipient BM‐chimeras and observed the accumulation of Ag‐responsive T cells in the liver 2 dpi with MOG35‐55/CFA by bioluminescence imaging (Fig. 15A). Fig. 15B shows that  the number of DCs (CD11c+) and adoptively  transferred 2D2 T cells (CD4+/Vβ11+) is drastically increased in the liver in mice lacking SLTs.  In order to demonstrate that the observed lymphocyte accumulations in the liver can  support  cell‐expansion,  we  injected  naïve  (CD62L+)  CD4+  T  cells  derived from 2D2 Tg mice into NIKaly/aly BM‐chimeras and subsequently immunized them with  MOG35‐55/CFA.  5  dpi,  livers  were  analyzed  for  Ag‐specific  CD4+  T  cell proliferation. Even  in normal mice, we find a  large number of expanded T cells within the liver (Fig 15C), but one could argue that they have immigrated from their  initial priming site,  the draining LN. However,  in  the absence of SLTs,  the livers of NIKaly/+NIKaly/aly  spl BM‐chimeric mice are sufficient  to propagate Ag‐
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driven T cell expansion and accumulation. In order to confirm that Ag‐specific T cell  proliferation  occurs  in  situ  in  the  liver,  we  administered  BrdU  i.p.  into NIKaly/aly  BM‐chimeras  7  dpi with MOG35‐55/CFA.  30 min  after  BrdU  injections, the mice were sacrificed and livers were analyzed for proliferating (BrdU+) CD4+ T cells by flow cytometry. Fig. 15D and E reveal the presence of BrdU+ cells in the livers  of  both  NIKaly/+NIKaly/+  and  NIKaly/+NIKaly/aly  spl  BM‐chimeras.  The number  of  BrdU+  T  cells  in  the  liver  is  increased  in  NIKaly/+NIKaly/aly  spl  BM‐chimeras compared to the controls. The fact that we found such a rapid (30 min) emergence  of  proliferating  T  cells  even  in  normal  mice  in  which  SLTs  are present, indicates that some degree of liver‐initiated CMI occurs simultaneously to the priming within draining LNs .     
       
 
Figure  13.  Extra­lymphoid  aggregates  in  the  liver  host  T  cells  and  APCs.  (A)  Liver cryosections from NIKaly BM‐chimeras immunized s.c. with MOG35‐55 (d7) were stained with H&E.  Bar: 500 μm. (B) Higher magnification image indicated by the region square in (A) stained with H&E and mAbs against CD3 and CD11c. Bar: 100 μm. 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Figure 14. Expression of lymphoid structure markers in livers of NIKaly BM­chimeric mice. Liver  cryosections  from  NIKaly BM‐chimeras  immunized  s.c.  with MOG35‐55  (d11)  were  stained with antibodies against CD4, CD8, CD11b, CD11c, CD19, CD62L, CD68, FDC, ICAM, Ki67, PNA and VCAM. Bar: 200 μm 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Figure  15.  (A­B)  Accumulation  and  Ag­specific  T  cell  expansion  in  the  liver.  NIKaly  BM‐chimeras were injected i.v. with 8x106 Luc‐2D2 Tg CD4+ T cells and immunized s.c. with MOG35‐55/CFA. (A) 2 dpi, mice were injected with luciferin and after 10 minutes sacrificed. Livers and in control  mice  LNs  and  spleen  were  isolated  and  images  were  acquired  by  bioluminescence imaging  to  reveal  the  accumulation  of  the  injected  luciferase  positive  (Luc‐2D2)  cells.  (B) Absolute numbers of liver‐invading DCs and Ag‐specific T cells assessed from the percentage of CD11c+, CD4+ and Vβ11+ cells analyzed by flow cytometry. Numbers above the graph indicate the fold‐increase  of  liver‐invading  cells  of  NIKaly/+   NIKaly/aly  spl  (grey)  over  NIKaly/+   NIKaly/+ (black). (C) NIKaly/+  NIKaly/+ and NIKaly/+  NIKaly/aly spl BM‐chimeras were injected with 8x106 CFSE‐labeled naïve (CD62L+) CD4+ T cells derived from 2D2 transgenic mice and immunized s.c. with MOG35‐55/CFA. 5 dpi LNs (only in NIKaly/+  NIKaly/+) and liver‐invading cells were analyzed by  flow cytometry by gating on 2D2+ cells. (D­E) NIKaly/+  NIKaly/+    and NIKaly/+  NIKaly/aly  spl BM‐chimeras  were  immunized  s.c.  with  MOG35‐55/CFA.  (D)  7  dpi,  BM‐chimeras  were  injected with BrdU i.p. 30 min after BrdU injection, liver‐invading cells were analyzed by flow cytometry for BrdU+ CD4+ cells. (E) Absolute numbers of liver‐invading BrdU+ CD4+ T cells assessed by flow cytometry. NIKaly/+  NIKaly/aly spl (grey) and NIKaly/+  NIKaly/+ (black). 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THE ADULT LIVER CAN SUPPORT T CELL, BUT NOT B CELL PRIMING  In contrast  to our  findings which show that mice  lacking SLTs do not generate high‐affinity Ab‐responses, intranasal influenza infection of splenectomized LTα‐/‐ mice reconstituted with wt stem cells for instance can initiate the formation of extra‐lymphoid  follicles  within  the  lung  which  support  some  degree  of  B  cell maturation  and  Ab‐secretion  [24,26].  One  possible  explanation  for  these contrasting  observations  regarding  Ab‐production  is  that  in  our  case,  stroma cells such as FDCs cannot signal  through LTβR due  to  the mutation within NIK and that this could be the reason for our  inability to observe GC formation and Ab‐secretion,  while  Moyron‐Quiroz  et  al.  used  mice  in  which  the  stroma compartment  can  be  engaged  by  LTα/β  [114,  118].  To  definitively  address whether the stoma’s inability to signal through NIK is the reason for the weak B cell  response,  we  obtained  LN‐deficient  LTα‐/‐  mice  and  reconstituted  their hematapoietic  system  with  wt  stem  cells.  The  resulting  chimeras  were splenectomized  and  lacked  all  peripheral  SLT  (analogous  to  the NIKaly/+NIKaly/aly  spl).    Yet  in  contrast  to  NIKaly/+NIKaly/aly  spl,  wtLTα‐/‐spl chimeras have normal stromal cell function and FDCs are capable of responding to LTa/β. These mice were immunized s.c. and the formation of B cell maturation and Ab production was analyzed. Fig. 16A demonstrates that these wtLTα‐/‐spl chimeras behave exactly like NIKaly/+NIKaly/aly spl in regards to their inability to generate high Ab titers and to class switch.  In  a  comparative  fashion,  we  analyzed  the  histological  parameters  of  wtwt, NIKaly/+NIKaly/aly  spl  and  wtLTα‐/‐spl  chimeras  (Fig.  16B).  While  only alymphoplastic  mutants  revealed  the  presence  of  lymphoid  aggregates surrounding periportal areas of the liver, neither FDCs nor PNA positive clusters could be found, again supporting the notion that the surrogate structures in the liver support T cell  function but  fail  to  initiate the  formation of GCs needed for Ab‐affinity cell maturation and class switching. Lastly, the large number of Ki67+ cells  within  the  liver  aggregates  again  support  our  conclusion,  that  active proliferation within the liver can be induced by s.c. immunization (Fig 16B).      




Figure 16.  Surrogate liver aggregates support CMI, but not B cell maturation. Wtwt and wtLTα‐/‐  spl BM‐chimeric mice were immunized s.c. with MOG35‐55/CFA. (A) 11dpi titers  of  anti‐MOG  Abs  (IgG,  IgM  and  IgA)  were  determined  from  sera  by  ELISA  (n=4 mice/group).  (B)  Liver  sections  from  wtwt,  wtLTα‐/‐spl  and  NIKaly/+    NIKaly/aly  spl  BM‐chimeras  were  stained  with  Abs  against  CD4,  CD8,  CD11b,  CD11c,  CD19,  CD62L,  CD68,  FDC, ICAM,  Ki67,  PNA  and  VCAM.  Positively  stained  infiltrated  areas  of  14mm2  liver  sections were counted (n=4 mice/group).   PRIMING OF CYTOTOXIC ANTITUMOR T CELLS IS INDEPENDENT OF SLTS   While  we  have  demonstrated  the  development  of  TH  cell‐driven  autoimmune disease in mice lacking SLTs, we wanted to elucidate whether these mice are also capable  of  inducing  successful  CTL  immunity.  We  used  the  B16.F10  murine melanoma  model,  which  represents  a  lethal  and  poorly  immunogenic  cancer. Irradiated  GM‐CSF  expressing  B16.F10  cells  are  used  as  s.c.  vaccine  to  initiate potent  CD8+‐antitumor  immunity  against  live  parental  B16.F10  tumor  cells 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[119]. We injected irradiated B16.F10‐GM‐CSF cells s.c. into one flank of NIKaly/+ 
  NIKaly/+  and  NIKaly/+    NIKaly/aly  spl  chimeric  mice.  12  dpi,  mice  were challenged with parental B16.F10 cells injected into the opposite flank. Fig. 17A shows that NIKaly/+  NIKaly/aly  spl chimeric mice can elicit potent antitumor CTL responses revealed by the inhibition of tumor growth. Next we transferred CFSE‐labeled MHC class I restricted OVA‐TcR Tg OTI T cells into NIKaly/+  NIKaly/aly spl and NIKaly/+  NIKaly/+  BM‐chimeric mice  and  subsequently  injected  irradiated B16.F10 cells expressing OVA. 12 dpi,  livers and  in control animals also spleen and  LNs  were  analyzed  by  FACS  for  Ag‐specific  CD8+  T  cell  expansion.  As demonstrated in Fig. 17B, proliferation of CD8+ OTI cells was detected in the liver of mice lacking SLTs. Hence, even under conditions in which the draining LNs are considered  a  compulsory  site  hosting  the  encounter  of  captured  Ag  and infiltrating CD8+ T cells, we can detect potent T cell responses, which originate in the liver when SLTs are absent.  LIVER FOLLICLES ARE INDUCED BY IMMUNIZATION AND ABERRANT HOMEOSTATIC T CELL MIGRATION  We next wanted to address the relevance of the  liver to serve as an alternative priming site in a setting where LNs are present but T cell migration into LNs is defective.  To  this  end, we  analyzed plt/plt  (paucity  of  LN  T  cells) mice, which display undisturbed B cell zones but severely abrogated T cell zones due to the loss of CCL19 and CCL21, which results in the inhibition of both naive T cell and DC homing  into  SLTs  [120]. We  found  that plt/plt mice  too developed delayed but  fulminant  EAE  after  s.c.  immunization  with  MOG35‐55/CFA  (Fig.  17C). Examination  of  liver  sections  of  immunized  plt/plt  mice  again  revealed lymphocyte aggregates consisting mainly of CD4+ T cells and DCs within the liver (Fig. 17D). 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Figure  17.  CD8+  T  cell  priming  in  the  liver  and  lymphoid  aggregates  in plt/plt mice.  (A) Tumor progression of NIKaly BM‐chimeras. Mice were vaccinated  s.c. with 1x106 irradiated GM‐CSF‐B16.F10 cells  into one  flank and 12d  later, mice received 2x105  live B16.F10‐Luc cells  into the  opposite  flank.  Vaccinated  NIKaly/+    NIKaly/+:  ■,  non‐vaccinated  NIKaly/+    NIKaly/+:  □, vaccinated  NIKaly/+   NIKaly/aly  spl: ▲,  non‐vaccinated  NIKaly/+   NIKaly/aly  spl:  Δ.  (B)  NIKaly/+  NIKaly/+  and  NIKaly/+   NIKaly/aly  spl  BM‐chimeras  were  injected  i.v.  with  20x106  CFSE‐labeled splenocytes  from OTI  transgenic mice  and  s.c.  injected with  a mix  of  1x106  B16.F10‐OVA  and 1x106 B16.F10‐GM‐CSF cells. 12 dpi LNs (only in NIKaly/+  NIKaly/+) and liver‐invading cells were analyzed by flow cytometry for the proliferation of CD8+ OTI cells (Vα2+). (C) EAE progression of 
plt/plt  (□)  and  wt  (■)  mice  immunized  s.c.  with  MOG35‐55/CFA.  (D)  Liver  cryosections  from diseased plt/plt mice  (C) were  stained with mAbs  against  CD11c,  CD11b,  CD4,  FDC,  B220  and PNA. Bar: 100 μm. 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 Even  though  the  immunodeficiency  in NIKaly/aly mice was  thought  to  be  due  to their  alymphoplasia,  we  have  previously  reported  that  the  defect  in  CMI  in 
NIKaly/aly  mice  is  not  connected  to  their  lack  of  SLTs  but  that  NIK  activity  is critical  for  cellular  immune  function  [104].  CMI  could  be  induced  in  the  total absence of SLTs, when splenectomised NIKaly/aly mice were reconstituted with a wildtype (wt) hematopoietic system. However, CMI could not be induced in mice featuring  normal  SLTs  but  carrying  the NIKaly/aly  lesion  only  in  hematopoietic cells.  Although  a  critical  function  for  NIK  has  been  suggested  specifically  in  T cells by several reports [70, 102, 103, 105, 106], the data presented here suggest that  the  loss  of  T  cell  function  in NIKaly/aly  mutants  is  not  T  cell  intrinsic,  but rather  resulting  from  a  defect  in  accessory  leukocytes,  namely  DCs.  We  show here that NIK‐lesioned T cells are indeed capable of secreting effector cytokines and  acquiring  full  effector  functions,  depending  on  the  thymic  environment  in which they develop. Instead of a T cell intrinsic lesion, loss of NIK in thymic DCs imprints a  long‐lasting halt  in T cell effector  function.  If however, NIK‐deficient 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T cells mature within a thymic environment which hosts NIK, T cells gain proper effector  functions  regardless  of  their  NIK‐deficiency.  Thus,  we  propose  that thymic DCs, which so far have only been implemented in negative selection [121] and  the  induction  of  natural  regulatory  T  cells  (nTregs)  [122],  are  capable  of imprinting subsequent T cell effector function onto developing thymocytes. This ability of thymic DCs is strictly dependent on NIK.     LOSS  OF  NIK  FUNCTION  RESULTS  IN  REDUCED  T  CELL  PROLIFERATION, DIFFERENTIATION AND PRODUCTION OF EFFECTOR CYTOKINES.  We have  recently  reported  that NIKaly/aly mice  are  resistant  to  the  induction of EAE due  to  the  loss  of  function  of NIK within  the  hematopoietic  compartment and more specifically due to a defect in T cell priming, independent of the lack of SLTs [104]. Furthermore, NIKaly/aly T cells have been reported to be defective in proliferation and secretion of Il‐17, Il‐2 and GM‐CSF [70, 103, 105]. In line with these previous reports, we observed that in vitro polyclonally activated NIKaly/aly CD4+  T  cells  produced  less  effector  cytokines  (Il‐2,  IFNγ,  Il‐17)  whereas  the production  of  Il‐4  was  unaffected  (Fig.  18A).  This  suggests  a  T  cell  intrinsic impairment of T cell polarization conferred by the ablation of NIK‐signaling. To further investigate the requirement of NIK for antigen‐specific T cell activation, we  crossed  NIKaly/aly  mice  with  TCR‐transgenic  2d2  mice,  in  which  the  TCR recognizes  the  immuno‐dominant  epitope  of  the  myelin  oligodendrocyte glycoprotein  (MOG35‐55). As expected, NIKaly/aly‐2d2 T cells also  failed  to secrete effector  cytokines  upon  encountering  their  cognate  antigen  (Fig.  18B).  To exclude  the  possibility  that  the  observed  defects  were  caused  by  the developmental  malformations  of  SLTs  in  NIKaly/aly  mice,  we  generated  bone‐marrow  chimeric  mice  (BMCs)  in  which  wt  mice  were  reconstituted  with hematopoietic  stem  cells  from  either  NIKaly/aly‐2d2  or  NIKaly/+‐2d2  mice.  We found  that  even  if  most  of  the  CD4+  T  cells  carry  the  cognate  antigen‐specific TCR, NIKaly/aly‐2d2→wt BMCs retained their EAE‐resistance upon MOG35‐55/CFA 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immunization  (Fig.  18C),  emphasizing  the  critical  role  of  NIK‐signaling  for  the development of autoimmune responses.  Since T cells from NIKaly/aly‐2d2→wt BMCs fail to acquire pathogenic properties, we addressed their behaviour in antigen‐independent homeostatic expansion in lymphopenic Rag1‐/‐ mice. After adoptive transfer of CD4+ T cells from NIKaly/aly‐2d2→wt BMCs into Rag1-/- mice we observed a drastic reduction in homeostatic expansion  when  compared  to  T  cells  from  NIKaly/+‐2d2→wt  BMCs  (Fig. 18D). Upon  immunization  of  those  mice  with  MOG35‐55/CFA,  NIKaly/aly‐2d2  T  cells further failed to respond to their cognate antigen, whereas control NIKaly/+‐2d2 T cells strongly expanded (Fig. 18E). In addition, Rag1‐/‐ mice reconstituted with T cells  from  NIKaly/aly‐2d2→wt  BMCs  remained  completely  resistant  to  EAE, suggesting  that  NIKaly/aly‐2d2  T  cells  cannot  be  primed  by  NIK‐sufficient accessory cells (Fig. 18F). Taken together, the data support the notion that NIK‐deficiency indeed leads to a T cell intrinsic lesion.  







F) CD4+ T cells of NIKaly/aly‐2d2→wt or NIKaly/+‐2d2→wt BMCs were transferred into Rag1­/­ mice, respectively.  Homeostatic  expansion was  observed  by weekly  FACS  analysis  of  blood  samples 
(D). 30 days after adoptive CD4+ T cell transfer Rag1­/­ mice were immunized with MOG35‐55/CFA and observed for antigen‐driven expansion by FACS analysis of blood at day 7 post immunization (dpi) (E) and clinical signs of EAE (n=6) (F). Each graph shows 1 representative of 3 independent experiments. 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LOSS OF NIK RESULTS IN A PRIMARY APC DEFECT  Our  data  and  previous  reports  [103]  support  a  T  cell  intrinsic  role  of  NIK. However,  we  further  aimed  to  identify  the  role  of  NIK  in  the  accessory  cell compartment. BMCs were generated by transferring a 4:1 mixture of Rag1­/­ and 
NIKaly/aly‐2d2 BM into Rag1‐/‐ mice. In those mice, NIKaly/aly‐2d2 T cell progenitors are developing within a NIK‐sufficient accessory cell environment. Surprisingly, 




cells early in development.  (A) Lethally irradiated Rag1­/­ mice were reconstituted with BM of either NIKaly/aly‐2d2, NIKaly/+‐2d2 or a 4:1 mixture of Rag1­/­ and NIKaly/aly‐2d2 mice. 6 weeks after reconstitution BMCs were immunized with MOG35‐55/CFA and observed for clinical signs of EAE (n=6). (B) Lethally irradiated wt mice were reconstituted with BM of either NIKaly/aly, NIKaly/+ or a 4:1 mixture of Rag1­/­ and NIKaly/aly mice. 6 weeks after reconstitution CD4+ T cells were isolated and  stimulated  with  plate‐bound  α‐CD3/α‐CD28.  Supernatants  were  analyzed  by  ELISA.  Each graph shows 1 representative of 3 independent experiments. 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DCS MATURATION AND CO‐STIMULATION IS DEPENDENT ON NIK‐SIGNALING  The  most  prominent  accessory  cells  involved  in  the  induction  of  CMI  and antigen‐presentation  are  DCs.  It  has  been  reported  that  in  vitro NIKaly/aly DCs have defects  in  the expression of CD80, CD86 and MHCII as well as  in antigen‐presentation and their ability to drive T cell expansion [123‐125]. Also the ability of  T  cells  to  secrete  effector  cytokines  is  largely  dependent  on  the  capacity  of APCs to provide T cell instructive cytokines. In particular, the cytokines Il‐12, Il‐23  and  Il‐6  have  a  major  impact  on  the  polarization  of  effector  T  cells.  We investigated the ability of NIKaly/aly DCs to secrete these factors after stimulation with  anti‐CD40,  thereby  mimicking  T  cell‐APC  interactions.  Interestingly, activated  NIKaly/aly  DCs  secreted  significantly  lower  levels  of  the  pro‐inflammatory cytokine subunit Il‐12/Il‐23p40 (Fig. 20A, B; Fig. 21A, B). We could further observe a strong reduction of the pro‐inflammatory cytokine transcripts 
Il­12p35,  Il­23p19  (Fig.  21C)  and  protein  levels  of  Il‐6  (Fig.  20C).  This  data suggests that NIK‐signaling in DCs upon DC‐T cell interaction via CD40 is critical for the capacity of DCs to secrete T cell‐instructive cytokines.  







Figure 20: NIKaly/aly DCs are  restrained  in  secretion of pro­inflammatory cytokines.  (A­C) Splenic NIKaly/aly  or  control DCs  were  stimulated  in  vitro  with α‐CD40  and  IFNγ  for  24  hours. GolgiPlug  was  added  for  the  last  4  hours  of  culture.  Intracellular  anti‐Il‐12/Il‐23p40  FACS staining  was  performed  together  with  cell  surface  staining  for  CD11c  (A).  Supernatants  were analyzed by ELISA  for  Il‐12/Il‐23p40 (B)  and  Il‐6 (C). Each graph shows 1  representative of 3 independent experiments. 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NIKALY/ALY DCS ARE RESTRAINED IN T CELL PRIMING AND FAIL TO INDUCE EAE  In  order  to  verify  the  reduced  priming  capacity  of  NIKaly/aly  DCs  in  vivo,  we established a model based on diphtheria  toxin  (DTx)‐mediated cell  ablation,  in which  we  generated  a  NIK‐sufficient  immune  compartment  where  only  DCs carry  the  mutated NIKaly/aly  protein.  For  this,  a  1:1  mixture  of  CD11cDTR  and 
NIKaly/aly  BM  was  transferred  into  irradiated  wt  recipients  (Fig.  22A).  Upon injection  of  DTx,  DCs  of  CD11cDTR  origin  (NIK+/+)  are  depleted  while  mutant 
NIKaly/aly DCs  are  retained.  The  efficiency  of  DC‐ablation  was  above  90%  (Fig. 22B).  We  observed  a  significant  delay  in  disease  onset  with  decreased  CNS infiltration  of  T  cells,  and  particularly  Il‐17‐producing  T  cells,  in  DTx  treated 
CD11cDTR+NIKaly/aly→wt  BMCs  compared  to  DTx  treated  control 
CD11cDTR+NIKaly/+→wt BMCs (Fig. 22C, D, E). This finding strongly supports our previous in vitro and in vivo data and demonstrates that NIK‐signaling in DCs is critical for their ability to instruct T cell polarization and effector function.  







Figure  22:  Absence  of  NIK­signaling  in  DCs  significantly  delays  EAE.  (A)  Experimental scheme.  Lethally  irradiated WT mice were  reconstituted with  a  1:1 mixture  of CD11cDTR  and 
NIKaly/aly  or NIKaly/+ BM,  respectively.  Upon  i.p.  application  of  DTx,  CD11cDTR  (NIK+/+)  DCs  are depleted, while NIKaly/aly or NIKaly/+ DCs remain. All other immune cells are still present as NIK+/+. 
(B) Efficiency of DC depletion  in DTx‐treated CD11cDTR mice was analyzed by  flow cytometry. 
(C)  CD11cDTR+NIKaly/aly→wt  and  CD11cDTR+NIKaly/+→wt  BMC  mice  were  immunized  with MOG35‐55/CFA and  treated with DTx every second day. Mice were observed  for clinical  signs of EAE.  Three  individual  experiments  were  pooled  (n≥15/group).  (D)  FACS  analysis  of  CNS‐infiltrating  lymphocytes  in MOG35‐55/CFA  immunized DTx‐treated CD11cDTR+NIKaly/aly→wt and 
CD11cDTR+NIKaly/+→wt BMCs at peak disease (17 dpi). Several brains and spinal cords of each experimental group were pooled. (E) Splenocytes were isolated from MOG35‐55/CFA immunized DTx‐treated/untreated  CD11cDTR+NIKaly/aly→wt  and  CD11cDTR+NIKaly/+→wt  BMCs  and rechallenged  in  vitro  with  50µg/ml  MOG35‐55  peptide,  followed  by  Il‐17  Elispot.  Shown  are triplicates of pooled splenocytes of one experiment (n≥5/group). 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RESTORED NIK‐SIGNALING IN DCS BUT NOT IN T CELLS IS SUFFICIENT TO GENERATE PATHOGENIC T CELLS  To  ascertain  a  primary  role  of  NIK‐signaling  in  the  DC  compartment,  we generated  mice  in  which  NIK  expression  is  restricted  exclusively  to  DCs.  
R26StopFLNIKwt  mice  express  NIKwt  preceded  by  a  loxP‐flanked  neoR‐Stop cassette  and  followed  by  a  Frt‐flanked  IRES­eGFP  within  the  ubiquitously expressed ROSA26 locus [126].  Upon crossing to CD11c­cre mice, the neoR‐Stop is excised and NIKwt will be expressed only in CD11c+ cells, which are mainly DCs (these  mice  are  hereafter  called  DCNIK).  Upon  further  breeding  those  animals onto  the  NIK‐/‐  background,  we  generated  mice  that  express  NIKwt  in  DCs, whereas all other cells and tissues completely lack the ability to express NIK.  In  order  to  manipulate  the  expression  of  NIK  only  within  the  hematopoietic compartment  and  to  provide  a  normal  lymphoid  organ  structure,  we  again generated BMCs. We transferred BM of either DCNIK‐NIK‐/‐ or control DCNIK‐NIK+/‐ and NIK­/­ mice into lethally irradiated wt recipients. 6 weeks after reconstitution these  BMCs  were  immunized  with  MOG35‐55/CFA.  Strikingly,  both  DCNIK‐NIK‐/‐
→wt and DCNIK‐NIK+/‐→wt mice were fully susceptible to EAE, whereas control 
NIK‐/‐→wt  animals  retained  their  EAE‐resistance  (Fig.  23A).  Furthermore,  the secretion of pro‐inflammatory cytokines Il‐12/Il‐23p40 and Il‐6 in NIK‐sufficient DCs  of  DCNIK‐NIK‐/‐→wt  mice  was  largely  restored  (Fig.  23B).    The  exclusive presence of NIK in DCs rescued the secretion of Th effector cytokines Il‐17, IFNγ and GM‐CSF (Fig. 23C) after restimulation, regardless of the expression of NIK in T cells. These findings demonstrate that NIK‐signaling only in DCs is sufficient to generate auto‐aggressive T cells, even if these T cells themselves do not express functional NIK.   In  contrast,  when  we  expressed  NIK  exclusively  in  T  cells  by  breeding  the 
R26StopFLNIKwt  mouse with  CD4­cre  and NIK‐/‐  mice,  TNIK‐NIK­/­→wt  BMCs  did not  develop  any  clinical  signs  of  sickness  (Figure  24).  This  experiment  clearly demonstrated  that  the  expression  of  NIK  in  T  cells  is  elusive,  whereas  it  is absolutely required in DCs.  




(A)  DCNIK‐NIK­/­→wt  and  DCNIK‐NIK+/­→wt  BMCs  were  immunized  with  MOG35‐55/CFA  and observed  for  clinical  signs  of  EAE.  Shown  is  one  representative  of  3  independent  experiments (n=6).  (B)  Splenic  DCs  were  isolated  from  DCNIK‐NIK­/­→wt  and  DCNIK‐NIK+/­→wt  BMCs  and stimulated  in  vitro  with α‐CD40  and  IFNγ  for  24  hours.  Il‐12/Il‐23p40  and  Il‐6  secretion was measured  by  ELISA.  (C)  Splenocytes  of  MOG35‐55/CFA  immunized  DCNIK‐NIK­/­→wt  and  DCNIK‐





Figure  24:  Expression  of  NIK  in  T  cells  is  not 
sufficient  to  restore  EAE  susceptibility  in  NIK­/­ 
mice.  TNIK‐NIK­/­→wt  and  NIK+/­→wt  BMCs  were immunized  with  MOG35‐55/CFA  and  observed  for clinical  signs  of  EAE.  Shown  is  one  preliminary experiment (n=6). 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LOSS OF NIK‐SIGNALING CRITICALLY IMPAIRS THYMIC DCS FUNCTION  Our data thus far clearly show that NIK‐signaling in DCs is critical for T effector function. However,  if  the restoration of NIK‐signaling  in DCs alone reinstates T effector function, the fact that adoptively transferred mature NIKaly/aly T cells into NIK‐sufficient  recipients  fail  to  acquire  effector  function  represents  a contradiction.  Hence,  we  hypothesize  that  NIK‐signaling  in  thymic  DCs  is required to enable developing thymocytes to exit the thymus as fully functional T cells.  Therefore,  the  thymic  DC  compartment  of  NIKaly/aly  and  NIKaly/+  mice  was analyzed in detail. All three thymic DC subsets [127‐129], namely migratory and resident  conventional DCs  (cDCs)  (CD11c+CD172α+  and CD172α‐,  respectively) and  plasmacytoid  DCs  (pDCs)  (CD11cint  CD45RA+)  were  found  in  comparable numbers in NIKaly/aly and NIKaly/+ mice (Fig 25A). However, both cDCs and pDCs in NIKaly/aly mice expressed reduced levels of CD80, CD86 and MHCII (Fig. 25B), with the strongest reduction in the resident DC subset. The reduced levels of co‐stimulatory  molecules  and  MHCII  indicate  functional  impairment  of  APC properties. To  further  investigate  the phenotypic properties of NIKaly/aly  thymic DCs  we  performed  qRT‐PCR  analysis  for  various  chemokine  ligands  and receptors involved in thymic DC function [128]. NIKaly/aly thymic DCs revealed a strong reduction  in  the expression of CCL17, CCL19  and CCL21  (Fig. 25D).   The analysis  of  chemokine  receptors  further  revealed  an  overall  reduction  in  the levels of CCR2, CCR5, CCR6 and CCR7, but increased expression of CCR9 and TLR9 (Fig.  26).  To  further  assess  their  functional  capacities, we  co‐cultured NIKaly/aly and NIKaly/+  thymic  DCs with  2d2  CD4+  single  positive  (SP)  thymocytes  in  the presence of MOG35‐55. NIKaly/aly thymic resident DCs elicited reduced proliferation in 2d2 CD4+ SP thymocytes (Fig. 25C).  Taken  together,  we  found  that  NIKaly/aly  thymic  DCs  are  phenotypically  and functionally distinct from NIKaly/+ thymic DCs, thereby having a possible negative impact on T cell development.  





Figure 25: NIKaly/aly thymic DCs show reduced APC­capacity. (A) Flow cytometric analysis of thymic  DC  subsets  from  NIKaly/aly  and  control  animals.  pDCs  are  CD11cintCD45RA+,  thymic resident DCs are CD11c+CD172a‐ and thymic migratory DCs are CD11c+CD172a+. (B) Expression analysis  of MHCII,  CD80 and CD86 on  thymic DC  subsets. Dotted  lines  represent heterozygous control DCs, solid lines NIKaly/aly DCs and grey histograms unstained controls.  (C) Proliferation of CFSE‐labelled 2d2 CD4+ SP thymocytes after three days of co‐culture with thymic migratory (left) and  resident  (right)  DCs  in  the  presence  of  10  µg/ml  MOG35‐55.  Dotted  lines  represent  CFSE profile  after  stimulation  with  heterozygous  control  DCs,  solid  lines  NIKaly/aly  DCs  and  grey histograms  show unstimulated  cells. (D) RNA of FACS  sorted  thymic DC  subsets  from NIKaly/aly and NIKaly/+ mice was transcribed into cDNA and analyzed by qRT‐PCR for expression of different chemokines. Data is representative of 3 independent experiments.  




Figure 26: NIKaly/aly thymic DCs express a distinct pattern of receptors. RNA of FACS sorted thymic DC subsets  from NIKaly/aly  and NIKaly/+ mice was  transcribed  into cDNA and analyzed by qRT‐PCR for expression of different chemokine receptors and TLRs. Data  is representative of 3 independent experiments.    RESTORATION OF NIK IN DCS RESCUES FOXP3, RORγT AND TBET EXPRESSION IN DEVELOPING THYMOCYTES 
 Thymic  DCs  have  primarily  been  implicated  in  mediating  negative  selection [121].  However,  there  is  increasing  evidence  that  thymocyte  development  not only selects appropriate T cell receptors but also imprints effector function onto thymic  emigrants.  In  particular,  NIK  has  been  suggested  to  be  involved  in  the expansion of CD25+ CD4+ T cells [124, 130]. We found a 50% reduction in FoxP3+ Tregs  in  both  developing  and  mature  T  cells  (Fig  27A,  B).  Given  the  reduced effector  cytokine  expression  of  NIKaly/aly  T  cells,  we  speculated  whether  the observed decrease of natural occurring nTregs  in NIKaly/aly  thymi  is  the  result of altered  “licensing”  of  T cells  during  their  development.  Recently  thymic  T  cell lineage  commitment  has  been  expanded  to  other  lineages  including TH17  cells [131].  Therefore,  we  analyzed  the  gene  expression  of  lineage‐specific transcription  factors  in  CD4+  SP  cells  of NIKaly/aly  thymi  (Fig.  27C)  and  spleens (Fig. 27D) and found that also the expression of RORγt and Tbet was decreased, whereas  GATA3  was  not  affected.  This  suggests  that  the  ability  to  become 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effector  T  cells  including  nTregs,  TH1  and  TH17  cells  is  to  some  extent  already determined during thymic development, and that thymic DCs are crucial for this process.  To  verify  that  DC  restricted  expression  of  NIK  is  capable  of  restoring  early lineage commitment, we again generated DCNIK‐NIK‐/‐→wt and DCNIK‐NIK+/‐→wt BMCs  and  analysed  the  expression  of  transcription  factors  in  CD4+  SP thymocytes.  As  shown  in  Fig.  27E  and  27F,  DC‐restricted NIK  expression  fully restores RORγt, Tbet and also Foxp3 expression.  






(B).  (C­D) RNA of FACS sorted SP CD4+ thymic (C) and splenic (D) T cells of NIKaly/aly and NIKaly/+ mice  was  transcribed  into  cDNA  and  analyzed  by  qRT‐PCR  for  expression  of RORγt,  Tbet  and 
GATA3. Data is representative of 3 independent experiments (n=3). (E­F) DCNIK‐NIK­/­→wt, DCNIK‐
NIK+/­→wt and NIK­/­→wt BMCs were generated. Percentage of FoxP3+ cells in the thymi (E) and transcript levels of RORγt, Tbet and GATA3 in FACS sorted CD4+ SP thymocytes (F) were analyzed (n≥3). 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DISCUSSION   It  is  widely  accepted  that  SLTs  such  as  spleen  and  LN  provide  the  basis  for cooperative  interactions  between APCs,  T  cells  and B  cells  [109]. Whereas  the spleen’s major  role  lies  in  the protection against blood‐borne  infectious agents [132‐134],  LNs  drain  antigens  from  local  sites  of  infections.  SLTs  are  highly organized  structures  composed  of  well  defined  B  cell  and  T  cell  zones,  which bring APCs, T‐ and B cells in close proximity to efficiently enable scanning for the cognate  antigen  [135].  The  notion  that  SLTs  are  required  for  the  initiation  of adaptive immune responses is not only supported by the swelling of LNs after a local  infection, but also by the immunodeficiency of alymphoplastic mice which are  genetically  deficient  in  lymph  nodes.  Such  mice  were  frequently  used  to underline  the  importance  of  SLTs  in  forming  adaptive  immune  responses. However, there are a number of reports, which show that immunization‐induced expansion of T‐lymphocytes can occur outside of SLTs, while B cell maturation including the production of Abs is highly dependent on the topography in SLTs. I will aim to summarize studies, in which the resourcefulness of immunity prevails over  structural  constraints  of  such  SLTs.  Much  of  the  observed  phenomena discussed  here  can  be  explained  by  investigating  the  reliance  of  immunity  on SLTs during  the  evolution  from primitive  jawed  fish  to  complex mammals  and the implications for our current understanding of mammalian immunology. Further,  upon  revealing  that  the  lack  of  SLTs  is  not  the  main  cause  of  the immunodeficiency  of  NIKaly/aly  mice,  I  will  discuss  the  requirement  of  NIK  in adaptive  immunity  and more  precisely  in  CMI.  This  discussion will  lead  us  to novel mechanisms, which  facilitate  thymic  DCs  to  license  the  T  cell  repertoire early during development. 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THE  ROLE  OF  SLTS  FOR  THE DEVELOPMENT  OF  CELL­MEDIATED  IMMUNITY 
VERSUS HUMORAL IMMUNE RESPONSES  CAN  PRIMARY  IMMUNE  RESPONSES  ONLY  BE  INITIATED  IN  SPECIALIZED LYMPHOID STRUCTURES?  The  formation of an  immunological synapse has been studied  in great detail at the molecular  level.  For  instance  immunological  synapses  form  between  APCs and T  cells  in  vitro.  Both T‐  and B  cells  can be primed  in  vitro  using  receptor‐crosslinking  with  monoclonal  antibodies  (mAbs)  or  artificial  APCs  [136,  137]. Hence, such artificial microenvironments have not only enabled us to determine the molecular underpinnings of T‐ and B cell priming, but also demonstrate that the minimal requirements for priming are determined by molecular interactions, rather than the structural environment. Nevertheless,  for decades  it has been postulated  that  the  induction of adaptive immunity  occurs  in  organized  lymphoid  organs  [138].  Studies  in mice  lacking organized  lymphoid  tissues  (alymphoplastic)  have  emphasized  the pivotal  role of SLTs  in  the  initation of an  immune response. NIKaly/aly mice  lack LNs and PP and show disrupted architecture of the spleen and thymus [94, 99]. The NIKaly/aly phenotype is caused by a point mutation within the NIK, an important mediator of the alternative NFκB‐pathway, which plays a major role in the development of the embryonic anlage of SLTs [99, 139]. NIK transduces signals  from the TNFR family  that  leads  to  the  processing  and  cleavage  of  p100  to  p52  [123,  139]. Signaling  through  the  TNFR  family  is  involved  in  the  development  of  SLTs  via LTβ‐signaling, B cell maturation (via BAFF), and adaptive immune responses (via CD40) [64].  Before the role of NIK in adaptive immunity was suggested, NIKaly/aly mice were frequently  used  as  an  experimental  model  to  demonstrate  the  importance  of SLTs  for  the  induction  of  primary  immune  responses.  The  first  such discovery was the inability of these mice to reject allogeneic skin grafts, and was attributed to the lack of SLTs even before the origin of the NIKaly/aly mutation was revealed [94].  The  deficit  of  NIKaly/aly  mice  to  fight  viral  infections  such  as  lymphocytic choriomeningitis  virus  (LCMV)  was  explained  by  the  insufficiency  of  T  cell 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responses  due  to  the  lack  of  LNs  [109].  Similarly,  the  fact  that  NIKaly/aly  mice cannot reject tumors was explained by the fact that tumor cells or tumor Ags had no  LNs  to  migrate  to  and  were  thus  unable  to  induce  a  CTL  response  [100]. Another  group  showed  that  splenectomized  NIKaly/aly  mice  were  not  able  to reject  cardiac  allografts  [101],  again,  owing  to  the  lack  of  SLTs.  LTα‐/‐  mice, which also lack LNs and have a similar phenotype to NIKaly/aly mice, do not elicit a contact‐hypersensitivity response to epicutaneous hapten‐immunization, further indicating  that  LNs  are  required  for  induction  of  CMI  [108].  Finally, much  like NIKaly/aly mice, LTα‐/‐ mice show greatly reduced LCMV‐specific CTL responses as well  as  abnormal  CTL  effector  functions  to  herpes  simplex  virus  (HSV)  [140, 141]. Collectively, these results seem to suggest that primary immune responses to a whole variety of triggers, whether alloantigens, viruses, or tumors depends on the presence of normal SLT architecture.   HAS THE IMMUNODEFICIENCY IN NIKALY/ALY MICE BEEN PROPERLY INTERPRETED?  Apart  from  the  absence  of  LNs,  NIKaly/aly  mice  host  a  variety  of  other  serious immune  defects  such  as  reduced  immunoglobulin  (Ig)  production  and  isotype class switch, defective T cell function and homing responses [94, 105, 106, 142]. Until now, it has been somehow neglected that these defects could potentially be connected  to  the  role  of  NIK  in  cell  activation  rather  than  the  developmental defects.  Here, I summarize different mouse models used to study the importance of SLTs  to primary  immune responses, and present evidence  that potent T cell responses can in fact occur independent of SLTs. Several groups showed that NIKaly/aly, and the almost equivalent NIK‐/‐ mice are not only immuno‐compromised due to the lack of SLTs but also due to the loss of function mutation within NIK in immune cells. Apart from the vital role of NIK in LTβR signaling and LN formation, NIK has been implicated in a variety of cellular processes. It was shown that NIK‐deficient T cells produce less Il‐2 and GM‐CSF, and  have  proliferation  deficits  upon  TCR‐engagement  [70,  102,  105]. Furthermore,  recent  reports  demonstrated  that  NIKaly/aly  T  cells  cannot differentiate into Th17 cells and fail to become auto‐pathogenic when presented with cognate self‐antigen [103, 104]. By reconstituting wt mice with an NIKaly/aly 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hematopoetic system, we demonstrated that the failure to develop pathogenic T cells is not connected to the lack of SLTs but lies exclusively in the NIK‐mutation in  immune cells.  In addition, we and others demonstrated  the  inability of NIK‐deficient  T  cells  to  induce  EAE  and  to  develop  into  cytokine‐secreting  effector cells  [103,  104].  Furthermore,  several  reports  provided  evidence  that  NIK‐signaling  is  not  only  crucial  for  T  cells  but  also  for  professional  APCs.  For example  NIKaly/aly  DCs  have  been  shown  to  express  low  levels  of  MHCII  and costimulatory  molecules  such  as  CD80,  CD86  and  show  deficits  in  antigen‐presentation  to  and  activation  of  CD4+  T  cells,  including  also  the  expansion  of regulatory  T  cells  [124].  NIKaly/aly  DCs  further  display  a  reduction  of  CD40‐mediated  Il‐12  production  [143]  and  fail  to  cross‐prime  CTLs  to  exogenous antigen, seemingly due to multiple defects in antigen‐processing [125].   However,  after  reconstitution of NIKaly/aly mice with  a wt hematopoetic  system and  further  splenectomy,  mice  have  been  shown  to  mount  pathogenic  T  cell responses proving clearly that CMI can be induced in the absence of SLTs [104]. The observation that  the distinct structure of SLTs does not seem to be critical for  the  induction  of  CMI was  underscored  in  studies  using models  other  than NIKaly/aly  mice,  but  which  also  lack  or  have  otherwise  disrupted  SLTs (summarized  in  Table  2).    More  evidence  that  SLTs  are  not  vital  for  the development of CMI stems from the findings that mice  lacking LTβR and hence LNs are capable of mounting strong adaptive immune responses to neo‐ as well as auto‐antigen [104, 144]. In addition, LTα‐/‐ mice, which also lack LNs, are able to mount potent CMI [145] and they have been shown to generate even stronger responses than wt mice in an airway‐inflammation model [146]. Upon intranasal infection with  influenza,  LTα‐/‐ mice were  competent  to  generate  virus‐specific CD8+ T cells that produced IFNγ and exhibited killer‐activity [115]. Similarly to influenza infection, upon intranasal application, LTα‐/‐ mice cleared a productive murine gammaherpesvirus 68 (MHV‐68) infection and controlled latent infection with CTL‐activity comparable to wt mice, although with delayed kinetics [147]. Furthermore, LTα‐/‐ mice were able to reject allogeneic small bowel transplants and  skin  allografts  [148,  149].  Another  group  has  described  effective  T  cell priming  and  rejection  (albeit  in  an  impaired  fashion)  of  allografts  in splenectomized LTα‐/‐ and LTβR‐/‐ mice,  indicating that SLTs contribute but are 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not absolutely required for immune responses in transplantation settings [144]. Also  upon  gastrointestinal  infection  with  the  gut‐residing  protist  parasite 
Eimeria vermiformis, LTα‐/‐ mice recruited antigen‐specific Th1 cells  to  the gut, although  this  was  delayed  compared  to  wt  mice  with  intact  mesenteric  LNs (mLN)  and PP  [150]. We will  discuss  below how  some of  the  above‐described observations  (i.e.  responses  upon  lung  and  gut  infections)  can  potentially  be explained by  the  fact  that  local  inflammatory stimuli  cause  the development of TLTs.  More evidence, that CMI can be initiated in the absence of SLTs, comes from so‐called  plt  mice. Plt  mice  lack  the  chemokines  CCL21  and  CCL19  expression  in SLTs and are therefore characterized by a defect  in the homing of naïve T cells and DCs to LNs, PPs, and splenic white pulp [151‐154]. It was demonstrated that 
plt  mice  are  capable  of  mounting  robust  CD4+  T  cell  responses  upon  s.c. immunization with  OVA  peptide  and  contact‐sensitization  [155,  156].  Those  T cell responses in plt mice were even enhanced compared to wt mice and did not decline for the normal contraction‐phase, suggesting that the structure of SLTs, at  least  for  subcutaneously  delivered  antigens,  is  more  important  for  the elimination  of  effector  T  cells  than  the  actual  priming  and  expansion‐phase. Furthermore, plt mice  could  demonstrate  delayed  but  pathogenic  CD4+  T  cell‐mediated autoimmune disease when presented with  self‐antigen plus adjuvant [104]. Similar findings showed that  in an infectious model using LCMV, CTLs in 
plt mice  could also be primed efficiently outside of  the discrete T  cell  zones of SLTs [120].            


















     Definitions:  NIKaly/aly,  alymphoplastic;  CFA,  complete  Freund’s  adjuvant;  EAE,  experimental autoimmune  encephalitis;  i.n.,  intra‐nasal;  LCMV,  lymphocytic  choriomeningitis  virus;  LTα, lymphotoxin alpha;  MHV‐68, murine herpes virus; OVA, ovalbumin peptide   IN CONTRAST TO T CELL ACTIVATION, B CELL ACTIVATION AND CLASS SWITCHING DEPENDS STRICTLY ON INTACT LYMPHOID STRUCTURES  As discussed above,  there  is accumulating data suggesting that SLTs are not an absolute  requirement  for  the  induction  of  CMI.  However,  in  striking  contrast different  rules  seem  to  apply  for  the  induction  of  B  cell  mediated  humoral immunity. Neither LTα‐/‐, LTβR‐/‐, nor NIKaly/aly mice generate IgA Abs to a variety of  triggers  [94,  96,  97].  Similarly,  upon  s.c.  infection  with  inactivated  herpes simplex virus‐1 (HSV‐1), LTα‐/‐ mice do not produce HSV‐1‐specific IgG Abs [96]. LTβR‐/‐ mice also show strongly reduced IgG responses and affinity maturation to  immunization  with  4‐hydroxy‐3‐nitrophenol‐acetyl‐chicken  gamma  globulin (NP‐CG)  in  alum  [97].  LTα‐/‐  mice  immunized  s.c.  with  sheep  red  blood  cells (SRBCs) mount a strong  IgM response but  fail  to switch  to  IgG  [158]. Adoptive transfer studies of wt splenocytes into LTα‐/‐ mice or the reciprocal, showed that 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the failure of Ab class switching was not B cell intrinsic but rather due to the lack of GCs and FDC clusters in LTα‐/‐ spleens [158]. Furthermore, the LTα‐/‐ spleen is even  insufficient  to  provide  the  structural  needs  for  functional  memory  IgG responses  after  adoptive  transfer  of  sensitized  memory  cells  from  wt  mice followed by antigenic challenge, showing that splenic structure  is also required to  permit  an  isotype‐switched memory  Ig  response  [116].  Similar  results  have been observed by s.c. immunizing LTα‐/‐ mice that have been reconstituted with a  wt  immune  compartment  [104].  Although  IgM  levels  were  comparable  to controls, mice were not able to perform Ab class switch to IgG. Conversely, upon intranasal  infection with MHV‐68,  LTα‐/‐ mice mounted  high  titers  of  IgM  and different IgG classes [147], suggesting that the manner of antigen administration does matter. This observation was confirmed by two studies showing that upon intranasal  infection of  splenectomized LTα‐/‐ mice with  influenza  virus  elicited virus‐specific  IgM  and  IgG  Abs  [115,  118].  Again,  this  phenomenon  can  be explained by the emergence of TLTs within the lung and will be discussed below. The  inability  of  NIKaly/aly  mice  to  generate  productive  Ab‐responses  has  been described  thoroughly.  Just  like  LTα‐/‐  and  LTβR‐/‐ mice, NIKaly/aly mice  lack GC‐formations and are defective in both Ig isotype‐switch and hypermutation [95]. Upon  infection  with  vesicular  stomatitus  virus  (VSV)  or  vaccinia  virus  (Vacc), NIKaly/aly mice displayed delayed IgM responses and failed completely to generate virus‐specific  IgG  [109].  NIKaly/aly  B  cells  are  largely  unresponsive  to  CD40‐induced proliferation, Ig production and NF‐κB activation, suggesting an intrinsic defect [123]. The NIKaly/aly B cell  intrinsic defect was confirmed by the NIKaly/aly bone  marrow  (BM)  transfer  into  wt  mice,  which  also  resulted  in  poor  B  cell follicles  and  lack  of  isotype‐switching  even  in  the  presence  of  SLTs  and  FDC clusters in the spleen [102].  However, we have recently shed light on the issue of whether  SLTs  are  an  absolute  requirement  for  the  induction  of  humoral immunity.  By  the  transfer  of  wt  BM  into  NIKaly/aly    mice  and  splenectomy  we generated  a  model  that  lacks  all  SLTs  but  contains  a  functional  wt  immune system  [104].  Upon  s.c.  antigen‐administration  these mice  failed  to  generate  a productive Ab response or class switch. This  finding was supported by a study showing that Vacc‐specifc IgG responses could not be restored with an adoptive transfer of wt splenocytes into NIKaly/aly  mice [109]. 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Taken  together,  the  above data  suggests  that upon  respiratory  viral  infections, specialized  lymphoid  structures  in  the  lung  (TLTs)  can  be  assembled  upon inflammation independent of LTα‐signaling and provide the structural needs to B  cells  in  order  to  allow  class  switch  and  memory  formation.  However,  if conventional SLTs are absent and during different infection routes, antigen will not  lead  to  inflammation  in  the  lung.  The  absence  of  specialized  lymphoid structures will then lead to insufficient B cell priming and maturation. In spite of the  fact  that  some evidence  exists  that  splenic  autoreactive B  cells  can  expand and undergo  somatic  hypermutation  at  the T  zone‐red pulp  border  and not  in GCs  [159],  most  observations  indicate  clearly  that  B  cells  are  dependent  on lymphoid structures composed of FDC clusters and GCs.  In spite of the widely held belief that adaptive immunity in general requires the structural support of SLTs, there is ample evidence to indicate that only B cells, but  not  T  cell  are  dependent  on  SLT. We will  next  discuss  the  basis  for  these phenomena  by  exploring  the  development  of  dedicated  SLTs  during  the evolution of the immune system in vertebrates. 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THE  EVOLUTION  OF  LYMPHOID  TISSUES  AND  THE  IMPACT  ON  ADAPTIVE 
IMMUNITY  Vertebrates consist of two subphyla: that of jawless (Agnatha) and that of jawed (Gnathostomata)  vertebrates.  Both  subphyla  have  developed  an  adaptive immune  system  based  on  somatic  random  generation  of  a  clonally  expressed repertoire  of  lymphocyte  receptors.  These  adaptive  antigen‐receptors  are expressed  by  cells  of  mesodermal  origin,  i.e.  the  lymphocytes,  whose development  shares  a  network  of  transcription  factors  [160].  The  random combination of scattered genetic elements (Leucine‐rich repeats in Agnatha and Immunoglobulin  Superfamily  (IgSF)  in Gnathostomata)  is  the  source of  a  large diversity  of  receptors  and  Abs  [161].  Recent  studies  showed  that  the  variable lymphocyte receptors (VLRs) of Agnatha (i.e. in lampreys) are even more diverse and  efficient  in  antigen  recognition  than  originally  thought  [162‐165].  The Gnathostomata  Ab  repertoire  generated  by  RAG‐mediated  rearrangement  of IgSF  gene  segments  can be  further modified by  somatic mutation,  class  switch and  gene‐conversion,  which  involve  an  activation‐induced  deaminase  (AID) Apobec  family  member  of  cytidine  deaminase,  which  is  already  present  in Agnatha  [162,  163].  AID‐mediated  class  switch  can  be  found  from  tetrapods (amphibians) onwards [161]. Whatever the analogies and convergences between Agnatha  and Gnathostomata,  there  are  still major differences between  the  two subphyla  and  this  review  addresses  the  features  more  specific  of  the Gnathostomata  (IgSF  receptors,  affinity  maturation,  somatic  mutation,  class switch,  memory  formation).  Once  precise  data  on  the  lymphoid  tissue  of  the Agnatha  will  be  available  it  will  be  interesting  to  see  to  which  level  the convergence can be extended.  B‐  and  T‐lymphocytes  emerged  simultaneously  during  phylogeny  in  jawed vertebrates. At the molecular level of the receptors, no major element seems to be missing  in non‐mammalian vertebrates  for developing a mammalian‐type of immune  response  i.e.  with  high‐specificity  and  memory.  Yet  there  are differences.  Are  they  linked  to  the  organization  of  the  lymphoid  organs?  As discussed  above,  in  contrast  to  T  cells  mammalian  B  cells  have  become accustomed to organized lymphoid organs, whose physical organization shows a 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rare  example  of  a  progressive  complexity  within  the  phylum  [166].  The  basic evolution  of  lymphoid  organs  in  relation  to  various  aspects  of  the  immune responses  are  presented  in  Figure  28.  We  will  here  discuss  whether  the evolution of  such structures coincides with  the potent affinity maturation seen only in mammals. The complexification of SLTs might be responsible for the increased efficiency of the  immune  responses  and  the  selection  events  associated with  it  seen  as  one moves from ectotherms to endotherms. Increased efficiency does not mean that the  response  of  ectotherms  lack  completely  efficiency. We  are  talking  about  a hierarchy in efficiency and selection. Clearly without selection at all there would be no adaptive immune response.  Within  the  context  of  this  review  we  shall  not  cover  the  conserved  primary lymphoid  organs:  the  thymus  and  the  BM  or  their  equivalents,  which  remain unidentified in Agnatha but are well characterized in all Gnathostomata. We shall focus on SLTs of Gnathostomata, where T‐ and B cell responses are initiated. 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Figure 28: Lymphoid organs and immune responses across vertebrates The  figure  describes  the  complexification  of  lymphoid  organ  architecture  and  number  across Gnathosotmates in parallel with immune function parameters. 
Abbreviations:  AID,  Activation  induced  cytidine  deaminase;  Gen  conv,  gene  conversion;  LRR, Leucine  rich  repeat;  VLR,  Variable  lamprey  receptor;  RAG,  recombination  activating  gene;  Ig comb, possibility of combinatorial association of V(D)J elements; TCR, T cell receptor; Ab matur, antibody  affinity  maturation;  GALT,  gut‐associated  lymphoid  tissue;  DC,  dendritic  cell;  FDC, follicular dendritic cell; MHC, Major histocompatibility complex Adapted from the following references [161], [166], [167],[168], [169], [170], and [171].  LYMPHOID STRUCTURES IN VERTEBRATE EVOLUTION  
THE SPLEEN IN VERTEBRATE EVOLUTION  With its lymphoid white and hematopoietic red pulps the spleen is present in all gnathostomes. It filters the blood, removes damaged cells and plays an important role  in  immunity  towards  blood‐borne  antigens.  Cartilaginous  fish  spleen contains well‐defined, highly vascularized white pulp areas, with a central T cell zone containing a MHC class II+ DC network and Ig secretory cells, surrounded by smaller zones of B cells [172].  Bony fish spleen, despite a poor development of the white pulp, contain the basic elements  of  the  mammalian  spleen  but  few  cells  resembling  FDCs.  Special terminal capillaries,  the ellipsoids, have a  thin endothelial  layer surrounded by fibrous reticulum and with a sheath of macrophages that are involved in antigen‐trapping.  Lymphocytes  are  seen  in  their  vicinity  during  immune  responses. Consequently, ellipsoids have sometimes been interpreted as primitive GCs.  In  anuran  amphibians  (i.e.  frogs)  the  white  pulp  is  organized  in  follicles  with reticular  elements,  macrophages,  DCs,  T‐  and  B  cells.  T  cells  are  found  at  the periphery of  the follicles and B cell zones expressing AID [173] are central and fitted around the central artery. No GCs have been observed in any amphibians. In  reptiles,  the white  pulp  shows  a  higher  degree  of  compartmentalization.  Its periarteriolar  lymphoid sheath  (PALS) contain small  lymphoblasts, phagocytes, whereas  the  periellipsoid  lymphoid  sheath  (PELS)  contain  medium‐sized lymphocytes and cells resembling FDCs but canonical GCs are absent [166].  Bird  spleen  resemble  that  of  reptiles  more  than  that  of  mammals  [174].  It contains  3  distinct  areas:  PALS,  PELS,  and  follicles  with  GCs.    Birds  are  the earliest vertebrates to show this specialized structure. 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In  addition  to  the  above‐mentioned  conserved  features,  the mammalian white pulp  nodules  are  surrounded  by  a  marginal  zone  rich  in  macrophages (histoenzymatically  similar  to  the  ellipsoid‐associated  macrophages  of  fish), where  antigen  gets  trapped.  Follicles  of  the  mammalian  spleen  contain  GCs [166].   
THE GUT­ASSOCIATED LYMPHOID TISSUES IN VERTEBRATE EVOLUTION  Gut‐associated  lymphoid  tissue  (GALT)  is present  in  all  vertebrates  and  in  fact the  presence  of  lymphocytes  in  the  gut,  an  area  particularly  exposed  to pathogens,  has  suggested  the  conservation  of  a  common  mucosal  immune system  for  all  vertebrates.  “GALT”  is  essentially  a  geographical  denomination and  the  cells  and  structures  found  there  may  differ  in  their  significance. Lymphoid aggregates seen in mesentery and the lamina propria are frequent in cold‐blooded vertebrates but do not represent well‐organized lymphoid organs [166]. The synthesis of  IgX, an analog of  IgA,  is  secreted by plasma cells  in  the gut‐epithelium of Xenopus whereas many T cells are found in the lamina propria. They most likely correspond to SLTs engaged in responses [175]. In fish a highly diversified  alpha‐beta  TCR  repertoire  is  maintained  in  intraepithelial lymphocytes in the absence of PPs and mLNs [176]. PPs are seen only in birds and mammals. They appear as oval or round lymphoid follicles  (similar  to LNs)  located  in  the  lamina propria  layer of  the mucosa and extending  into  the  submucosa  of  the  ileum.  In  adults,  B‐lymphocytes predominate in the follicles' GCs, whereas T cells are located between follicles. In ruminants  the  large  ileal PP  functions  in  fact as a bursa‐like primary  lymphoid organ [177].  
LYMPH NODES IN VERTEBRATE EVOLUTION  There  are  no  LNs  in  fish,  and  none  of  the  lymph  glands,  cavity  bodies,  jugular bodies  of  amphibians  have  a  LN  architecture.  They  are  blood‐filtering  organs without any connection to lymph. However, in reptiles (lizard) some aggregates 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form  nodules  associated  with  the  lymphatic  network  resembling  LNs  of primitive mammals such as the echidna [166]. Duck  "lymph  nodes"  have  been  described  but  there  are  very  few  of  them  and their structure is different from that of mammals even though they show GCs and post capillary venules for recirculation [178]. By definition, LNs with a canonical architecture  are  not  seen  before mammals,  where  they  can  be  very  abundant (e.g.  500  to  600  in  humans).  They  are  particularly  efficient  during  responses against  antigens  present  in  the  specific  tissue  thanks  to  their  lymphatic  vessel system. They consist of a cortical region with primary follicles rich in B cells and FDC. T cells and DCs are found in the paracortex. Macrophages and plasma cells reside in the medullary region of the node. The compartmentalization of the cells within the node is under the control of a complex network of chemokines [179].   In  summary,  while  all  jawed  vertebrates  have  true  SLTs,  ectotherms  lack  LNs and organized GALTs. GCs with many FDCs are not  formed after  immunization until  the  phylogenetic  position  of  birds  that  are  also  the  first  vertebrates possessing  LN‐like  architecture,  although  not  at  all  to  the  same  extent  as mammals, which stand out  in  terms of  the organization of  their SLTs and their ability to generate high affinity Igs.    THE IMMUNE RESPONSES OF JAWED VERTEBRATES WITH A SPECIAL EMPHASIS ON COLD‐BLOODED VERTEBRATES   For  a  long  time  it  has  been  claimed  that  virtually  no  affinity maturation  took place  in  fish,  amphibians,  or  reptiles.  The  existence  of  immunological memory has  also  been  questioned,  especially  in  fish.  Following  the  discovery  of hypermutation in cartilaginous fish, immune responses have been reinvestigated 
in  vivo.  Following  an  injection  of  a  T‐dependent  antigen,  the  affinity  of  the monomeric  IgM  and  an  unusual  heavy  chain  homodimeric  isotype  IgNAR  in sharks  (Ginglymostoma  cirratum)  increases  about  10‐fold  over  7‐9  weeks [180],[181]. A quicker secondary response can also be demonstrated but without an  increase  in  titers over those  in  the primary response. The production of  the 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monomeric IgM, a subclass of shark heavy chain [182], is probably not due to a switch  but  due  to  the  involvement  of  distinct  cell  lineages  committed  to  one isotype  or  the  other  [183]  and  not  yet  fully  understood.  In  the more  recently evolved  bony  fish  (teleosts)  such  as  the  trout,  immunological  memory  is demonstrable  either by  the  success of  some vaccines or by  immunization with sheep red blood cells as antigen. The anamnestic character (i.e.  faster response and higher Ab titers) of the secondary response against this T‐dependent antigen was demonstrated at 24° C and 20° C but lost at 18° C [184]. T cell functions are notoriously  impaired  at  low  temperature  [185].  Minor  increases  in  affinity maturation in the trout are attributed to selections of either minor pre‐existing B cell  populations  or  of  somatic mutants.  So  far,  no  switch has  been  reported  to any  of  the  newly  discovered  non‐IgM  isotypes.  Isolation  of  TCR  genes  and  the existence of polymorphic MHC I and II molecules in teleosts suggest that antigen presentation  is  operative.  Indeed,  following  an  acute  infection  with  viral hemorrhagic  septicemia  virus,  complementary‐determining  region  (CDR)‐specific T cell clonal expansion and TCR CDR3 profiles were skewed for several Vb /Jb combinations [186].   Among anuran amphibians (i.e. frogs), Xenopus responds specifically to many T‐dependent antigens, with restricted Ab heterogeneity and a modest (4‐10  fold) affinity maturation following immunization with the nominal antigen DNP‐KLH. The  memory  response  peaks  at  2  weeks  instead  of  3‐4  and  is  10  to  40‐fold higher,  but  there  is  no  further  change  in  affinity  over  the  initial  rise.  Somatic mutations occurring at hypermutation rates in the VH of B cells from immunized animals, were not strongly localized in CDRs [187]. Thus paradoxically, there is in  principle  no  shortage  of  variants,  and  the  reasons  for  the  poor  Ab  affinity maturation might  be  a  less  than  optimal  selection  in  the  absence  of  GCs.  Yet, although affinity maturation does not  appear  to occur,  isotype‐switch  to  IgY  is observed. This depends on T cells and does not occur at low temperatures. Other essential T cell functions in immune responses were demonstrated with thymus‐dependent  allograft  rejection  studies  and  with  in  vitro  assays  for  T–B collaboration  and  MHC  restriction.  Histologically,  Ab‐forming  cells  can  be observed scattered in the white pulp of the spleen or in proliferation foci in the liver both of Alytes larvae and in Xenopus larva and adults [188, 189], where they 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might correspond to the genesis of TLTs [190]. Urodele amphibians such as the newt  elicit  low  IgM  Ab  heterogeneity  and  they  respond  poorly  to  thymus‐dependent  antigens  even  though  their  expressed  TCR  diversity  looks  normal. This  might  also  be  related  to  the  fact  that  the  urodele  spleen  is  not  clearly divided into white and red pulp. Much less data are available in reptiles although the  lack of  an  increase  in  affinity  and  low Ab heterogeneity has been  reported [191,  192].  There  is  currently  no  data  on  T  cell  effector  functions  of  reptiles during an immune response. In  birds,  chicken  Ig  sequence  data  and  light  chain  patterns  on  2‐D  gel electrophoresis showed less Ab heterogeneity than the mouse. A poor increase in affinity maturation of chicken Ab responses has been reported. However ducks display  Ab  responses,  affinity  maturation  (ca.  400  fold)  and  memory  to immunization  with  TNP‐KLH  or  TNP‐HIgG  (both  T‐dependent  antigens)  and adjuvants  [193].  These  results  could  be  explained  with  the  existence  of  non‐conventional  LNs  in  the  duck  whereas  these  organs  have  not  been  found  in chickens.   In  conclusion,  although  all  Gnathostomata  have  the  potential  for  generating diverse  Abs  after  immunization,  only  homeothermic  vertebrates  such  as mammals make the most of this potential through the process of efficient affinity maturation.    Besides  the  phylogenetically  universal  T‐dependent  allograft rejection;  memory,  specificity,  and  some  comparatively  modest  affinity maturation, have now been demonstrated in fish and amphibians, yet often only with  difficulty.    Somehow  the  immune  responses  of  ectotherms  remind  of mammalian in vitro immune responses that are separated from the architecture of the lymphoid organs.  The next big step in the evolution of the immune system is the emergence of highly sophisticated SLTs dedicated to the formation of GCs. This lead to a drastic increase in Ab‐affinities, whereas T cell responses have not changed much  during  evolution  of  Gnathostomata.  On  the  other  hand,  even  in the  absence  of  such  dedicated  lymphoid  structures,  T  cells  have  consistently shown the resourcefulness to initiate immune responses in order to protect the host. 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RESOURCEFUL IMMUNITY AND THE CONVERSION OF UNCONVENTIONAL LYMPHOID ORGANS   We  discussed  above  how  local  inflammation  can  lead  to  the  emergence  of  so‐called  TLTs.  A  de  novo  appearance  of  proliferating  lymphocyte  aggregations defined  as  inducible  bronchus‐associated  lymphoid  tissues  (iBALTs)  was observed in the lungs of LTα‐/‐ mice, which most likely served as the priming site for  virus‐specific  CTLs  [118].  The  iBALT  structures  have  further  been demonstrated  to  be  sufficient  for  the maintenance  of  immunological  memory, therewith  also  providing  the  structural  requirements  of  secondary  immune responses [114]. iBALTs are induced after airway‐infection or inflammation and are  organized  by  B  cell  follicles  around  networks  of  FDCs,  separated  by interfollicular regions containing DCs and T cells, with high endothelial venules (HEV)  expressing  the  L‐selectin  ligand  peripheral  node  addressin  (PNAd), facilitating  the  recruitment  of  naïve  T  cells  [118,  194].  These  highly  organized lymphoid  structures  potentially  facilitate  T‐  and  B  cell  activation  with  class switch as described earlier.  The  list  of  organs  capable  of  developing  TLTs  upon  chronic  inflammation  is  a long one.  Chronic  inflammatory diseases  in  the CNS as well  as  in other organs such  as  the  joints  or  thyroid  develop  features  reminiscent  of  lymphoid  tissues [195‐199]. Several  reports have described how prolonged  inflammation during MS can lead to the formation of B cell follicles including FDCs in the meninges of the CNS [200, 201]. Similarly, upon cryptogenic fibrosing alveolitis, the lung will form  tissues  with  ectopic  B  cell  follicles  [202,  203].  Chronic  inflammatory diseases  of  the  gut  such  as  ulcerative  colitis  or  Crohn`s  disease  cause  the neogenesis  of  gut‐associated  lymphoid  tissue  (GALT)  [204‐206]  and  chronic hepatitis  C  patients  develop  FDC‐containing  ectopic  follicles  in  the  liver  [207, 208].  Finally,  T  cell  aggregates with HEV‐like  vessels  can  be  found  in  livers  of patients  with  primary  sclerosing  cholangitis  [209,  210].  Thus,  lymphoid  neo‐organogenesis  can  be  found within many  organs  in  patients  with  a  variety  in chronic inflammatory diseases of infectious or autoimmune origin.  However,  as  can  be  seen  in  the  many  examples  described  above,  the  site  of lymphoid  neo‐organogenesis  usually  seems  to  be  connected  to  the  site  of 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inflammation.  Surprisingly,  we  recently  discovered  that  upon  s.c.  delivery  of antigen, proliferating lymphocyte aggregates were found in the periportal areas of the liver [104], meaning that the site of inflammation was distant from the site of immune cell priming.  This implies that antigen‐sampling DCs coming from the skin actively  selected  the  liver as a priming  site  for T  cells.  In  fact, we  showed that  APCs  including  DCs  picked  up microspheres  from  s.c.  immunizations  and transported them actively into the liver indicating that not only T cells, but also APCs  display  plasticity  and  resourcefulness  in  order  to  initiate  immune responses outside of  SLTs. Other groups have also demonstrated  that  the  liver can  facilitate  local T cell priming  [211].   The  liver  therefore distinguishes  itself from  other  organs  developing  TLTs  in  that  it  can  prime  T  cell  responses  both locally  and  distally  to  the  site  of  antigen  exposure.  Interestingly,  upon  liver transplantation  in  patients,  recipients  often  inherit  allergies  from  their  organ‐donors [212], indicating that the liver is a common host to a variety of cells of the adaptive  immune  response.  Just  as  thymus  and  BM  are  places  of  adult hematopoiesis,  the  liver  carries  out  this  task  during  embryogenesis  and therefore  serves  transiently  as  a  lymphoid  organ  [213].    Perhaps  the  liver “remembers” its task in adulthood and can resume its original function if needed. However,  the  lymphoid  aggregates  found  in  the  liver,  that  were  described  to raise  CMI  in  the  absence  of  SLTs,  did  not  show  any  evidence  of  providing  the structural elements needed for B cell priming, such as FDCs or peanut agglutinin (PNA) positive markers [104]. CMI has also been shown to be initiated in other organs such as BM. For example, treatment of mice with the Mel‐14 monoclonal Ab  to  the  LN  homing‐receptor  CD62L,  limits  trafficking  of  naïve  and  central memory T cells into the LN through HEVs [214, 215]. Upon intranasal influenza infection  of  Mel‐14‐treated  splenectomized  mice,  virus‐specific  T  cells  were found  in  the BM,  suggesting  that BM can supplant  the SLT as a  site of primary immune response [157]. The possibility to find effector T cells in the BM due to contamination  from  the  blood  or  ongoing  virus  infection  within  the  BM  was excluded in these studies. Finally, a study has described that blood‐borne antigen can  lead  to  proliferation  and  differentiation  of  naïve  T  cells  into  effector  and memory cells within the BM which is driven by BM‐resident DCs [117]. 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SLTs are a convenient place  to concentrate Ag and T cells and  in  their meeting within  SLTs  speed  up  the  process  of  T  cell  priming.  Nonetheless,  I  have highlighted  here  several  evidences,  that  in  the  absence  of  SLTs,  the resourcefulness and pressure on immunity is sufficient to permit T cell priming outside of SLTs even in distant organs such as the liver (subcutaneous Ag) or BM (blood‐borne Ag). However,  priming  then occurs  at  a decreased pace probably due  to  the  low precursor  frequency of  antigen‐specific T  cells.  In  contrast  to T cells  however,  highly  organized  lymphoid  structures  seem  to  be  obligatory  for sophisticated  B  cell  activation  including  high‐affinity  maturation  and  class switching.  Interestingly, this hypothesis is strongly supported by what we know about the evolution  of  immunity.  B‐  and  T  cell  receptors  evolved with  the  conversion  of RAG to mediate somatic recombination in jawed vertebrates. While all jawed fish demonstrate  adaptive  immune  functions,  Ig  class  switching  appeared  from  the tetrapod stage of evolution onwards, whereas GC‐formation and development of LNs  is  only  visible  from  birds  onwards.  The  finding  that  LNs  are  not  a prerequisite  for T cell priming has major  implications for our understanding of the  development  and  evolution  of  adaptive  immune  responses  and  is  of  great interest  in  the  context of  vaccination. While  intranodal  immunization has been considered as an effective route of vaccination, recent findings suggest that in the context  of  CMI,  this  concept  needs  to  be  revised.  T  cells  may  not  need  to  be primed  in  tissue‐draining  LNs,  but  they  can  be  primed  within  the infected/inflamed  tissue or  even  in organs distant  to  the  target  tissue where a minimum, yet sufficient, amount of as yet unidentified elements exist to ensure antigen‐presentation  and  sustained  proliferation.  The  liver  has  been demonstrated to host such an evolutionarily conserved pathway for successful T cell priming independent of lymphoid tissues. This is a good example in which an important  function such as host‐defense  is not dependent on a single pathway, but ensures that fail‐safe solutions are in place. The evolutionary conservation of such default pathways  is an  indication of  the strength of  the selection pressure on the immune system to find a niche for lymphocyte priming to protect the host. 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THE ROLE OF NIK­SIGNALING IN CELL­MEDIATED IMMUNITY   It is widely held that non‐canonical NFκB‐signaling is predominately involved in the  formation  of  SLTs.  Consequently,  the  apparent  immunodeficiency  of  the 
NIKaly/aly  strain was  considered  as  evidence  for  the  requirement  of  SLTs  in  the formation of CMI [23]. In recent years, it has however become evident that non‐canonical  NFκB‐signaling  is  also  applied  by  other  cell  types  such  as  B  cells, osteoclasts,  cancer  cells  and  also  by DCs  and T  cells,  suggesting  a  role  of  non‐canonical  NFκB‐signaling  in  adaptive  immune  responses  [103‐106,  124,  125]. The inability of NIKaly/aly mice to mount CMI is independent of the developmental lymphoreticular malformations but  a  result  of  the  interrupted NIK‐signaling  in hematopoietic  cells  [104].  Yet  the  mechanistic  consequences  of  lesioned  NIK‐signaling  in  DCs  and  T  cells  remain  poorly  understood  or  might  have  been wrongly interpreted.   NIK‐SIGNALING IN T CELL FUNCTION  Recently, it has been reported that NIK‐/‐ T cells adoptively transferred into Rag2­
/­  mice  fail  to  develop  encephalitogenic  properties  and  to  secrete  pro‐inflammatory  cytokines  [103].  The  authors  concluded  that  NIK‐/‐  T  cells  are intrinsically defective and that non‐canonical NFκB‐signaling in T cells is vital for the  acquisition  of  an  effector  phenotype.  This  assumption  is  corroborated  by previous reports showing that NIKaly/aly T cells secrete reduced levels of Il‐2 and GM‐CSF [105]. Indeed, we confirmed a drastic reduction in the secretion of pro‐inflammatory  cytokines by NIKaly/aly T cells  and  their  failure  to homeostatically expand. In addition we found NIKaly/aly T cells to be anergic towards their cognate antigen  and  to  thus  fail  to  acquire  pathogenic  properties  in  the  context  of autoimmune disease. However, our observation that T cell  function is  impaired as  a  result  of  the  loss  of  NIK  in  hematopoietic  accessory  cells  and  more specifically  in DCs challenges the concept of a T cell  intrinsic defect  in NIKaly/aly mice. Two independent experimental setups demonstrated that the T cell defects are  the  result  of  a DC  intrinsic utilization of NIK:  on one hand  the presence of 
NIKaly/aly DCs together with wt T cells in vivo is sufficient to significantly diminish 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EAE development (Fig. 22) and on the other hand NIK‐/‐ T cells can differentiate into  fully  functional, auto‐aggressive T cells, when NIK  is  restored  in accessory cells (Fig. 19). When the expression of NIK is transgenically restricted to DCs via the CD11c promoter, CMI is fully restored even if T cells are NIK­/­ (Fig. 23). One caveat is that CD11c‐cre is also active in a small population of T cells. This small population of transgenic NIK‐expressing T cells could potentially be involved in the  rescue  of  immune  function  in  DCNIK‐NIK­/­  BMCs.  However,  this  is  most unlikely  because  i)  we  did  not  observe  a  preferential  accumulation  of  NIK‐expressing GFP+ T cells in the inflamed CNS at peak disease in DCNIK‐NIK­/­ BMCs (data not shown), ii) T cell function of mixed Rag1‐/‐+NIKaly/aly→Rag1‐/‐ BMCs is fully  restored  even  though  the  entire  T  cell  compartment  is NIK‐deficient,  and most importantly iii) TNIK‐NIK­/­ BMCs were not susceptiple to EAE. Interestingly,  adoptively  transferred  adult  NIKaly/aly  T  cells  fail  to  acquire pathogenicity  but  rather  displayed  an  anergy‐like  state,  although  they  were primed by NIK‐sufficient accessory cells (Fig. 18). Only upon undergoing thymic development  in the presence of NIK‐sufficient accessory cells could T cells give rise  to  pathogenic  effector  cells  (Fig.  19).  Taken  together,  this  suggests  that against  current belief, NIK  is  largely dispensable within T  cells.  In  contrast we suggest that the anergic T cell phenotype observed in NIKaly/aly and NIK­/­ mice is caused  by  defective  T  cell  development  due  to  dysfunctional  thymic  DCs.  We therewith propose that NIK‐signaling is critical in DCs in order to licence T cells during thymic development and avoid anergy.    NIK‐SIGNALING IN DC FUNCTION  A role for non‐canonical NFκB‐signaling in DCs has already been suggested, but the precise  impact  on T  cell  function has not been addressed before. While on one hand it was claimed that CD40‐mediated activation of DCs is independent on NIK  [102, 123, 216], other reports have demonstrated  that peripheral NIKaly/aly DCs  express  fewer  co‐stimulatory  molecules  and  show  reduced  APC  capacity, which  then  results  in  diminished  T  cell  proliferation  [124].  Furthermore, 
NIKaly/aly DCs show a decreased ability to induce the expansion of CD25+ CD4+ T cells  in  vitro  [124].  Additional  reports  claim  that  NIKaly/aly  DCs  are  unable  to 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cross‐prime  CD8+  T  cells  to  exogenous  antigen,  involving  multiple  defects  in antigen‐processing pathways  [125]. Also  the secretion of  the pro‐inflammatory cytokine  Il‐12  but  not  Il‐6  upon  CD40‐mediated  activation was  reported  to  be decreased in NIKaly/aly DCs [143].  We confirmed  that splenic NIKaly/aly DCs express  less MHCII and co‐stimulatory cytokines  (data not  shown)  and produce  less  Il‐12/Il‐23p40 protein. We  could further observe a reduction in transcript levels for Il­12p35 and Il­23p19 as well as  reduced  Il‐6  protein  levels.  Furthermore,  we  now  show  evidence,  that 
NIKaly/aly DCs are hampered  in  the priming of CD4+ auto‐reactive T cells  in vivo (Fig. 22). However,  the  relevance of NIK‐signaling  in  thymic DCs has until now not been addressed, most  likely  due  to  the  incomplete  understanding  of  the  function  of thymic DCs in general.  NIK‐SIGNALING IN T CELL DEVELOPMENT  T  cell  development  requires  NFκB‐signaling  (reviewed  in  [60]).  In  particular, thymocytes  require  predominantly  canonical  NFκB‐signaling  at  various  stages during  development.  NFκB1  is  activated  by  the  pre‐TCR,  acts  pro‐apoptotic  in negative  selection  and  anti‐apoptotic  in  positive  selection,  promotes  long‐term survival  and  is  required  to  generate  Tregs.  In  contrast,  non‐canonical  NFκB‐signaling  plays  a  major  role  in  the  development  of  lymphoid  structures. Disrupted  NIK‐signaling  leads  to  the  absence  of  LNs  and  to  structural malformations  in thymus and spleen. The structure of  the thymus with  its well organized  cortical  and  medullary  regions  is  believed  to  be  critical  to  allow proper  T  cell  development.  Within  this  process,  thymocytes  are  migrating through  these  specific  regions  in  a  highly  organized manner,  passing  different checkpoints  where  they  undergo  various  selections  in  order  to  become  fully mature  T  cells  without  autoimmune  potential.  In  this  context,  autoimmune regulator  (Aire),  a  transcription  factor mainly expressed by mTECs  that  is  also regulated  by  the  non‐canonical  NFκB‐axis,  seems  to  play  an  important  role  in negative selection by driving the expression of peripheral‐tissue antigens (PTAs) [217]. 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However, we have now shown, that not only CMI can be initiated independent on a certain structure of SLTs, but also  the  tight structure of  the  thymic stroma  is dispensable  in  order  to  develop  mature  T  cells:  NIKaly/+→  NIKaly/aly  BMCs generated  T  cells,  that  underwent  thymic  development  within  a  disorganized thymus of NIKaly/aly stromal origin. These T cells were able to develop full effector capabilities,  showing  that  the  tight  stromal  structure  of  the  thymus  was  not critical  for  T  cell  development  [104].  In  contrast,  we  found  that  the  proper thymic  stromal  structure  of  NIKaly/+ mice  was  not  sufficient  to  rescue  T  cell functionality  of NIKaly/aly  origin.  However,  the  expression  of  NIK  exclusively  in DCs was able to restore functionality within NIK‐deficient T cells, although only when DCs were NIK‐sufficient during  the development of NIK‐deficient T  cells.  This  implies  that  a  population  of  DCs  in  the  thymus  is  more  vital  to  the development of thymocytes than the thymic stromal structure. Indeed, different populations of  thymic DCs have been described within  the  last  years,  although their function in T cell development remains elusive. Currently, three phenotypically distinct thymic DC subsets have been described, namely  pDCs,  CD172α+CD11b+CD8α‐/lo  migratory  cDCs  and  CD172α‐CD11b‐CD8αhi  thymic  resident  cDCs  [127].  One  important  function  of  thymic  DCs appears to be negative selection at the CD4 SP stage in T cell development [121, 218‐220].  In  this  context,  death  due  to  high‐affinity  interaction  or  due  to  no interaction  (death by neglect)  are not  the only  fates of developing  thymocytes, but  also  the  generation of nTregs  or  induction of  anergic T  cells  [221‐223]. The mechanistic  underpinnings  of  these  processes  are  up  to  today  poorly understood. Although  the complete  lack of DCs  seems  to have  little effect on T cell development and negative selection [224], a diverted function of thymic DCs is expected to have consequences on T cell development.  The expression of various CCRs and chemokines in thymic DC subsets has been analyzed, described and compared excessively  to expression profiles of  splenic DCs, but the physiological relevance for most of them remains unclear [128]. We also  profiled  thymic  DCs  of  NIKaly/aly  mice  and  found  strongly  reduced  gene expression  of CCR2, CCR5, CCR6  and CCR7.  It  has  been  proposed  that many  of these CCRs are important for the localization and migration of DCs into lymphoid tissues  in  general  including  the  thymus  [220].  We  further  observed  a  strong 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reduction in the expression of the chemokines CCL17, CCL19 and CCL21 in thymic DCs  of NIKaly/aly  mice  (Fig.  25).  Especially  CCL17,  CCL19  and  CCL21  have  been described as important chemokines to direct intrathymic migration of positively selected thymocytes from the cortex to the medulla [128, 225].  Thymic dendritic cells have been proposed to induce FoxP3‐expression and the formation of nTregs  [226]. Taking this  into consideration, our data suggests that 
NIKaly/aly  thymic  DCs  might  be  defective  in  the  induction  of  nTregs  (Fig.  27). Recently it became evident, that other T effector cell lineages, such as Th17 cells, can at  least partially be  licensed already during thymic development [131]. We found  that  also  Tbet  and  RORγt‐expressing  CD4+  SP  T  cells  are  decreased  in thymi of NIKaly/aly mice. (Fig. 27). This phenotype and also the decrease in nTregs is  rescued  in NIK‐/‐  CD4+  SP T  cells  of DCNIK→wt BMCs. We  therefore  propose that  NIK‐signaling  in  thymic  DCs  is  crucial  to  imprint  developing  T  cells  to subsequently  aquire  full  effector  capabilities  and  to  avoid  progression  into  an anergic state.  DOES NIK‐SIGNALING EQUAL NON‐CANONICAL NFκB‐SIGNALING?  Several  reports  claimed  that under  specific  circumstances, NIK  signals  into  the canonical NFκB‐pathway [67, 81, 82]. Curiously, even though both NFκB2‐/‐ and NIKaly/aly mice show impaired T and B cell  responses, both have also been reported  to contain  lymphocyte  infiltration into  various  organs  similar  to  that  of  Aire‐/‐  mice  [227‐231].  However,  the autoimmune  phenotype  in NFκB2‐/‐  and NIKaly/aly mice  seem  to  originate  from the stromal compartment, as transplantation of NFκB2‐/‐ and NIKaly/aly thymi was sufficient to induce the breakdown in self‐tolerance [227, 228]. The phenotype of tolerance breakdown in both NFκB2‐/‐ and NIKaly/aly mice seems to be mediated by  the  absence  of  Aire‐signaling  in mTECs  [227]  via  the  non‐canonical  NFκB‐signaling cascade [228]. Instead, the impairment of T cell responses in NIKaly/aly mice results from disrupted NIK‐signaling in hematopoetic cells. Surprisingly, in contrast  to  NIKaly/aly  mice,  NFκB2‐/‐  mice  do  not  show  any  defect  in  Treg generation neither  in  spleen nor  in  thymi  [227].  Furthermore, DCs of NFκB2‐/‐ 
      DISCUSSION                          
  104 
mice express increased levels of MHCII and co‐stimulatory molecules as well as an enhanced ability to induce CD4+ T cell responses [232]. We also observed that RelB‐/‐→wt  BMCs  are  fully  susceptible  to  EAE  (Figure  29).  These  observations suggest, that the signaling‐cascade, by which NIK executes its function in CMI, is not  via  the  p52‐dependent  non‐canonical  NFκB‐pathway.  However,  by  which mechanism  and  signaling  cascade  NIK  conducts  its  function  in  thymic  DCs  in order to licence developing T cells remains unclear.    
 
Figure 29: RelB­/­→wt  BMCs are  susceptible 
to  EAE.  RelB‐/‐→wt  and  wt→wt  BMCs  were immunized  with  MOG35‐55/CFA  and  observed for  clinical  signs  of  EAE.  Shown  is  one preliminary experiment (n=4‐6).        NFκB‐SIGNALING IN AUTOIMMUNITY  NFκB  is  constitutively  activated  in  many  autoimmune  diseases,  including diabetes  type  2,  systemic  lupus  erythematosus  and  rheumatoid  arthritis  [84]. Because NFκB plays  a  central  role  in  differentiation,  activation  and  survival  of cells, it contributes to autoimmune diseases in multiple ways. Because NFκB acts in  both  T  and  B  cell  development,  defects  in  these  processes  may  initiate pathogenicity. NFκB plays a pro‐apoptotic role  in the negative selection of self‐reactive B and T cells. In the periphery, NFκB is essential for the maintenance of B  cell  homeostasis.  Defects  may  lead  to  prolonged  survival  of  B  cells  with autoimmune  reactivity  [233]. NFκB  is  further  required  for  the  development  of mTECs  and  the  organization  of  the  thymic  stroma,  and  the  development  and differentiation of DCs  [228, 234‐236]. Mice  lacking mTECs,  thymic structure or DC subtypes are often characterized by severe autoimmunity with autoreactive T cells, multiple  organ  lymphocytic  infiltrates  and  in  some  cases  early mortality 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[228,  235].  NFκB2‐deficiency  leads  to  a  milder  phenotype,  likely  because  of compensation  by  NFκB1.  In  the  absence  of  NFκB2,  NFκB1  can  form heterodimers with RelB and might  therewith  replace p52/RelB. Combined Bcl‐3/NFκB2‐deficiency  (complete  lack  of  NFκB‐signaling)  leads  to  a  dramatic autoimmune  phenotype,  caused  by  a  complete  lack  of mTECs  and  consequent loss  of  negative  selection  of  auto‐reactive  T  cells  [237].  Also  defects  in  the upstream  activators  of  the  canonical  and  non‐canonical  NFκB‐pathways  effect the establishment of self‐tolerance. For example TRAF6‐deficiency also leads to thymic disorganization, reduced Treg‐production, absence of mature mTECs and autoimmunity  [236,  238].  Although  TRAF6  classically  activates  the  canonical NFκB‐pathway,  it  might  also  indirectly  effect  the  non‐canonical  pathway  as TRAF6‐deficiency leads to the lack of RelB expression in mTECs, that again leads to  reduced  Treg  generation  [238].  In  contrast,  the  lack  of  TRAF3,  which  is  a negative  regulator  on  the  non‐canonical  NFκB‐pathway,  leads  to  an  increased activation  of  NFκB2.  The  B  cell‐specific  TRAF3‐/‐  results  in  prolonged  B  cell survival,  greatly  an  expanded  B cell  compartment  and  autoimmune  reactivity [233]. Many autoimmune diseases are characterized by the development of TLTs at the site  of  inflammation  (as  described  above).  The  non‐canonical  NFκB‐pathway may  be  implicated  in  the  generation  of  TLTs  as  the  constitutive  expression  of LTβ  has  been  shown  to  induce  TLTs  [239].  Furthermore,  most  autoimmune diseases are displaying elevated levels of the cytokine BAFF that is needed for B cell maturation  and  survival  [240]  and  signals  via  the  non‐canonical  pathway. Additionally,  NIK‐deficient mice  are  not  only  resistant  to  EAE,  but  also  largely resistant  to  rheumatoid  arthritis  and  inflammation‐induced  osteoclastogenesis [241].  Lastly, most autoimmune diseases are characterized by the expression of many pro‐inflammatory  cytokines,  such  as  Il‐6,  Il‐1,  TNF‐α  and  Il‐17,  that  play  an important  role  in  sustaining  the  inflammation  by  recruiting  and  activating immune  cells  to  the  site  of  inflammation.  Most  of  these  pro‐inflammatory cytokines  induce  NFκB‐pathways  and  treatments  targeting  the  signaling  via these cytokines seem to be effective in attenuating pathogenicity [242]. 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Taken together,  improperly regulated NFκB‐signaling leading to its constitutive activation  results  in  autoimmunity.  Autoimmune  diseases  may  be  caused  by malfunctioning  lymphocytes  whose  apoptotic  pathways  are  blocked  by abnormal  NFκB‐activation,  enabling  the  survival  of  self‐reacting  cells.  The multiple  roles  of  NFκB  in  autoimmune  diseases  make  it  an  important pharmaceutical target. However, because NFκB is involved in many crucial roles that maintain health  in general,  the challenge  lies  in  finding a balance between avoiding  deleterious  side  effects  caused  by  systemic  NFκB‐inhibition  and  the treatment of disease‐specific symptoms. 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CONCLUSION  Alymphoplastic NIKaly/aly mice  lack LN and PPs due  to a point mutation  in NIK, which  is  the  main  mediator  of  non‐canonical  NFκB‐signaling.  They  are  highly immunodeficient  and  resistant  to  EAE.  Defining  the  reason  of  its immunodeficiency,  we  found  that  T  cell‐driven  immune  responses  are independent  of  SLT  structures, while  B  cell  responses  strongly  depend  on  the topography of  dedicated  lymphoid  tissues.  This  phenomenon  can be  explained by  the  emergence  of  high  affinity  maturation  and  class  switch  of  antibodies during  evolution,  which  coincided  with  the  appearance  of  defined  lymphoid structures, whereas T cells were generally as effective as they are today before LNs developed.  While the EAE resistance of NIKaly/aly mice was not connected to the lack of SLTs, it was caused by the lack of NIK in hematopoietic cells. CMI could not be induced in  mice  that  were  deficient  of  NIK  in  all  immune  cells  but  had  normal  SLTs. However, NIK was not required in T cells themselves, but was rather essential in thymic  DCs  to  allow  proper  T  cell  development.  We  have  therewith  not  only demystified the true reason of CMI immunodeficiency in NIKaly/aly mice but also identified  a  novel  function  in  thymic DCs:  the  capacity  to  shape  the  T  effector repertoire early during development. 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EXPERIMENTAL PROCEDURES  
Mice, bone marrow transplantation and splenectomy  C57BL/6  and Rag1‐/‐  mice  were  purchased  from  Janvier  Laboratories,  France. 
Alymphoplasia mice (Map3k14aly mice here depicted as NIKaly/aly) were obtained from  Clea  laboratories  Japan  and  bred  in  house  under  SPF‐conditions. Heterozygous NIKaly/+ mice were used as controls for homozygous NIKaly/aly mice. 
NIK­/­  mice  on  129Sv/Ev  background  were  generously  provided  by  Robert  D. Schreiber  (Washington University,  St.  Louis, MO, USA)  and bred onto C57BL/6 background  in  house  for  ten  generations.  Both NIKaly/aly  and NIK‐/‐  mice  were maintained by heterozygous breedings. 2d2 (MOG‐TCR Tg) mice were provided by  V.  Kuchroo  (Harvard  Medical  School,  Boston,  Massachusetts),  LTβR‐/‐  and LTα‐/‐  mice  were  provided  by  A.  Aguzzi  and  M.  Heikenwalder  (University Hospital  Zurich,  Zurich,  Switzerland)  and  OTII  and  OTI  mice  were  purchased from Jackson Laboratories. Luciferase (pbActin‐Luciferase) transgenic mice were obtained from C. Contag (UCSF) and crossed to the 2D2 mice (Luc‐2D2). Plt/plt mice  were  obtained  from  B.  Ludewig  (Kantonsspital  St.Gallen,  Switzerland). 
CD11cDTR mice were provided by Steffen  Jung (Weizmann Institute of Science, Rehovot,  Israel).  CD11cCre  mice  were  generously  provided  by  Boris  Reizis (Columbia  University,  New  York,  NY,  USA).  R26StopFLNIKwt  and  all  other  mice were maintained under specific pathogen‐free conditions. 
Bone marrow chimeric mice (BMCs) were generated as described previously [243, 
244]. Briefly, mice were lethally irradiated with a split-dose of 1100 rad. Femur, tibia 
and pelvis of donor animals were flushed with PBS to obtain BM stem cells. 10x106 
cells were injected intravenously (i.v.) per mouse. Mice were treated with 0.2% 
BORGAL in drinking water for 3 weeks to prevent bacterial infections. Mice were splenectomized  as  described  previously  [245].  Animal  experiments  were approved by the Swiss veterinary Office (68/2003, 70/2003, 10/2006 , 13/2006 
and 55/2009; Zurich, Switzerland). 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Induction of EAE and DTx treatment  MOG35‐55 peptide (MEVGWYRSPFSRVVHLYRNGK) was obtained from GenScript. EAE was  induced as described previously  [246]. Briefly, mice were  immunized s.c. with 200µg of MOG35‐55  emulsified  in CFA  (Difco)  and  two  i.p.  injections  of  200ng  pertussis toxin on day 0 and 2. BMCs did not receive pertussis toxin. For adoptive transfer MOG‐reactive lymphocytes were generated as described [246]. For  EAE  experiments with DTx  treatment, mice were  injected  i.p. with  400 ng DTx  (Calbiochem)  one  day  before  immunization  and  then  200  ng  DTx  every second day for the entire length of the experiment. Each time point shown is the average disease score of each group ± SEM. 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Proliferation assay Mice  were  injected  i.v.  with  20x106  CFSE  (carbofluorescein  diacetate succinimidyl  ester)‐labeled  (Invitrogen‐Molecular  Probes)  (10μM)  splenocytes obtained from either 2D2, OT‐II or OT‐I TcR Tg mice or with 8x106 CFSE‐labeled naïve  CD4+  2D2  Tg  T  cells  (isolated  with  CD4+CD62L+  isolation  kit  from Miltenyi). Mice were subsequently immunized s.c. with 200 µg of MOG35‐55 /CFA (Adjuvant  complete  H37  Ra,  DIFCO)  (for  2D2),  OVA323‐339  /CFA  (for  OT‐II)  or with a 1:1 mix of irradiated 2x106 B16.F10‐GM‐CSF/B16.F10‐OVA cells (for OT‐I). 4 or 5 dpi (12 dpi for OT‐I) mice were sacrificed and spleen, LNs (if present) and livers were analyzed by FACS for the proliferation of CD4+ T cells using the clonotypic TcR and CFSE‐fluorescence (2D2: TCR Vα3.2 Ab, OT‐II and OT1: Vα2 Ab).  
 
Histology Tissues were freshly snap‐frozen in liquid nitrogen. To determine infiltration of inflammatory  cells,  tissue  sections  were  stained  with  hematoxylin  and  eosin (H&E)  or  with  the  following  mouse‐specific  antibodies  (Abs)  as  previously described [246]: anti‐CD11c (Jackson ImmunoResearch Labs), anti‐CD11b (BMA Biomedicals),  anti‐CD3,  anti‐CD4,  anti‐FDC  M1  and  anti‐Thy1.1  (BD‐Pharmingen).  GC  cells  were  stained  with  peanut  agglutinin  (PNA;  Vector Laboratories).  
 
Flow cytometry For cell surface staining, we used the following antibodies (Abs): CD11c, CD11b, Iab, CD80, CD86, CD172a, CD45RA, CD4, CD8, Il‐12/Il‐23p40, Vα3.2, Vβ11, Thy1.1 (BD  Pharmingen).  Intracellular    FoxP3  stain  was  performed  according  to manufacturers  instructions  (eBioscience). Cells were  incubated with Abs at  the optimal  concentration  for  20  min  at  4°  C  and  cells  were  analyzed  with  FACS Canto II (BD Pharmingen) and FACS Diva Software. Postaquisaition analysis was performed  with  either  FACS  Diva  or  FlowJo  (TreeStar)  software. Cytofluorometric  analysis  of  CNS  invading  lymphocytes  has  been  described 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previously  [247].  For  intracellular  cytokine  staining  cells  were  treated  with GolgiPlug  (BD  Biosciences)  for  the  last  4  hours  of  culture.  After  Ab  surface staining,  cells  were  permeabilized  with  Cytofix/Cytoperm  (BD  Biosciences) according to manufacturer`s recommendations and stained intracellular with Il‐12/Il‐23p40‐specific Ab (BD Pharmingen).  To trace the distribution of Ag after  immunization, mice were  injected s.c. with 200 µl  FluoresbriteTM  Carboxylate  (YG)  or  Polychromatic  Red  (PR)  1.0 micron microspheres (Polysciences) emulsified in CFA. 7 days after injection mice were euthanized  with  CO2  and  organs  were  removed  to  isolate  lymphocytes  as described  above.    Single  cell  suspensions  were  analyzed  by  FACS  for  the presence of FITC+ or PE+ cells. For FITC skin painting, mice were painted on the shaved  flanks  with  100 µL  of  5 mg/ml  fluorescein  isothiocyanate  (FITC) (Molecular Probes) dissolved in 1:1 acetone:dibutylphtalate. On day 1, mice were euthanized with  CO2  and  organs  removed  and  analyzed  by  FACS  as  described above.   
Delayed­type hypersensitivity (DTH) assay Mice  were  immunized  s.c.  with  100  μg/flank  of  MOG35‐55  peptide  ,  or  KLH (Sigma) emulsified in CFA. 11dpi, mice were challenged by injecting 10 μg/10μl of MOG35‐55 peptide, KLH, PBS into the dorsal surface of the ear. DTH responses were  determined  by measuring  the  ear  thickness  using  a  calliper  micrometer (Mitutoyo)  24  h  after  challenge  and  Δ  ear  swelling  was  established  by  the increase in ear thickness over baseline (pre‐challenge ear thickness).  
 
Enzyme­linked immunosorbent assay (ELISA) for antibody detection Plates  were  coated  with  10μg  rMOG1‐121  in  0.1  M  NaHCO3  (pH  9.6)  at  4°  C overnight  or  KLH  (Sigma)  and  blocked with  1%  (w/v)  bovine  serum  albumin (BSA).  Diluted  sera  were  incubated  for  2h  at  RT.  After  washing,  peroxidase‐conjugated antibodies  to mouse Ig’s,  IgG,  IgA,  IgM (Sigma) were added (1:1000 diluted)  and  incubated  for  1h  at  RT.  Plates  were  washed  and  chromogen (Biosource) was added. Absorbance was measured on a micro plate reader (450 nm) (Bio‐Rad). 
 





Bioluminescence imaging To  visualize  Luc‐2D2‐cells,  mice  were  injected  i.p.  with  3  mg  of  Luciferin (Xenogen)  prior  to  bioluminescence  imaging  using  an  IVIS100  imaging  station (Xenogen). The luminescent image was overlaid on the photographic image.  
 
Bromodeoxyuridine (BrdU) treatment Mice were immunized s.c. with MOG35‐55/CFA. 7 dpi BrdU (BD Pharmingen) (2.5 mg) was  injected  i.p.  30 min  before  the mice were  sacrificed  and  analyzed  for proliferating  (BrdU+)  CD4+  T  cells  by  flow  cytometry  with  anti‐BrdU  Ab (eBioscience).   
Tumor induction Mice  were  s.c.  vaccinated  into  one  flank  with  irradiated  (6000  rads)  1x106 B16.F10‐GM‐CSF cells. At day 12 after vaccination, mice were injected with live 2x105  B16.F10‐Luc  cells  into  the  opposite  flank.  Each  time  point  shown  is  the average tumor size of each group ± SEM measured using a caliper.  
Isolation of splenic DCs and in vitro stimulation Spleens were removed under sterile conditions. Each spleen was injected with a cocktail  of  1  mg/ml  liberase  and  0.5  mg/ml  DNaseI  (Roche)  in  medium  and incubated  at  37°  C  for  20  min.  Single  cell  suspensions  were  prepared  by homogenizing  the  tissue  between  glass  slides  and  filtering  through  70  μm  cell strainers  followed by  erythrocyte  lysis.  Splenic DCs were  isolated with CD11c+ positive  magnetic  selection  according  to  the  manufacturer’s  instructions (Miltenyi Biotech).  
                                                                                                                                         EXPERIMENTAL PROCEDURES                          
  114 
DCs  were  plated  at  a  concentration  of  1x106  cells/ml  in  RPMI‐1640  medium supplemented  with  10%  FCS,  1%  L‐glutamine  and  1%  penicillin‐streptavidin (Invitrogen Life Technologies), and stimulated for 6 to 24 hours at 37° C 5% CO2 with  10  μg/ml  α‐CD40  (BioXCell;  FGK  4.5)  and  20  ng/ml  IFNγ  (Peprotec). Supernatants were analyzed for Il‐6 and Il‐12/Il‐23p40 using ELISA according to manufacturer`s instructions (BD Pharmingen).   
Isolation of thymic DCs and in vitro co­culture assays Thymic  DCs  were  isolated  as  previously  described  [248].  Briefly,  thymi  were digested  in  IMDM  containing  2%  FCS,  25mM HEPES,  0.4mg/ml  Collagenase  D (Roche)  and  DNAse  for  40  min  at  37°  C.  Afterwards,  high‐density  cells  were separated from low‐density cells by using a discontinous Percoll density gradient (GE Healthcare, ρ=1.115 and ρ1.055). After removal from the gradient cells were washed and stained with antibodies against CD11c, CD8, CD172a and CD45RA, followed by sorting into migratory DCs (CD11c+ CD172a+), resident DCs (CD11c+ CD172a‐)  and  pDCs  (CD11cint  CD45RA+)  on  a  FACSAria  (BD).  Purity  was routinely >95%. For  in  vitro  culture  20.000  DCs were  cultured with  100.000  sorted  and  CFSE‐labeled  CD4+  thymocytes  or  peripheral  T  cells  in  the  presence  of  10  ug/ml MOG35‐55 and 10 ng/ml Il‐7. Analysis was performed after 72 hours of culture.  
Peripheral  CD4+  T  cell  purification,  in  vitro  stimulation  and  adoptive 
transfer Splenocyte  single  cell  suspensions were  prepared  as  described  above.    CD4+ T cells  were  purified  with  CD4+  negative  magnetic  selection  according  to  the manufacturer’s  instructions  (Miltenyi Biotech). The purity was  routinely >95% as confirmed by flow cytometry.  For  in  vitro  stimulations  of  splenic  CD4+  T  cells,  3x106  CD4+  T  cells/ml  were cultured  in RPMI‐1640 medium supplemented with 10% FCS, 1% L‐glutamine, 1% penicillin‐streptavidin.  Polyclonal CD4+ T cell activation was performed with 5 μg/ml plate‐bound α‐CD3 and α‐CD28 for 48 hours. For antigen‐specific CD4+ T cell  activation whole 2d2 splenocytes were stimulated with 20 μg/ml MOG35‐55 and  5  μg/ml  soluble  α‐CD28  for  48  hours.  Supernatants  were  harvested  and 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concentrations  of  IFNγ,  Il‐17,  GM‐CSF,  Il‐2  and  Il‐4  were  quantified  by  ELISA according to manufacturers instructions (BD Pharmingen).  For  adoptive  transfer  experiments,  2x106  purified  splenic  CD4+  T  cells  in  PBS were  injected  i.v.  into  Rag1‐/‐  mice.  T  cell  reconstitution  of  Rag1‐/‐  mice  was monitored weekly by tail bleeding and flow cytometry.   
RNA isolation and quantitative (q) RT­PCR Total RNA was  isolated according  to manufacturer’s  instructions  (RNeasy Mini Plus Kit, Qiagen). Reverse  transcription was performed using random hexamer primers and Moloney murine leukemia virus reverse transcriptase (splenic DCs) or 
Superscript II (thymic DCs) (Invitrogen Life Technologies). cDNA was analyzed by 
quantitative real-time PCR (qRT-PCR) (Biorad) in duplicates using SYBR Green 
PCR Mastermix (Invitrogen) or hydrolysis TAMRA probes (Roche). The expression 
level of each gene was normalized to HPRT or DNA Polymerase II. The following 
primers purchased from Operon Technologies were used:  
 
HPRT (5’-GACCGGTCCCGTCATGC-3’, 5’-TCATAACCTGGTTCATCATCGC-
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